Details of Disease

General Information of Disease (ID: DIS8K27O)

• Disease Name: Ulcerative colitis
• Synonyms: ulcerative proctosigmoiditis; left-sided ulcerative colitis; ulcerative colitis; colitis ulcerative; ulcerative colitis (disease)
• Disease Class: DD71: Ulcerative colitis
• Definition: An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.
• Disease Hierarchy:
  DISAF7DD: Colitis
  DIS8K27O: Ulcerative colitis
• ICD Code:
  ICD-11: ICD-11: DD71
  ICD-9: ICD-9: 556
  Expand ICD-11: 'DD71
  Expand ICD-10: 'K51; 'K51.8; 'K51.9
  Expand ICD-9: 556
• Disease Identifiers:
  MONDO ID: MONDO_0005101
  MESH ID: D003093
  UMLS CUI: C0009324
  MedGen ID: 3532
  HPO ID: HP:0100279
  Orphanet ID: 771
  SNOMED CT ID: 64766004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 22 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Adalimumab	DMQMV1B	Approved	Antibody	[1]
Aminosalicylic Acid	DMENSL5	Approved	Small molecular drug	[2]
Budesonide	DMJIBAW	Approved	Small molecular drug	[3]
Corticotropin-zinc Hydroxide	DMZ1A1N	Approved	NA	[4]
Cortisone Acetate	DMG8K57	Approved	Small molecular drug	[5]
Etrasimod	DMT0A3Y	Approved	NA	[6]
Golimumab	DMHZV7X	Approved	Antibody	[7]
Hydrocortisone	DMGEMB7	Approved	Small molecular drug	[8]
Infliximab	DMH7OIA	Approved	Antibody	[9]
Levacecarnine hci	DMJBOCR	Approved	Small molecular drug	[10]
Mesalazine	DMOL5IU	Approved	Small molecular drug	[11]
Mirikizumab	DM7R3N5	Approved	NA	[12]
Naltrexone	DMUL45H	Approved	Small molecular drug	[13]
Olsalazine	DMZW9HA	Approved	Small molecular drug	[14]
Oprelvekin	DMTSRI6	Approved	NA	[10]
Ozanimod	DMT6AM2	Approved	NA	[15]
Prednisolone	DMQ8FR2	Approved	Small molecular drug	[16]
Sulfadiazine	DMTW3R8	Approved	Small molecular drug	[17]
Sulfasalazine	DMICA9H	Approved	Small molecular drug	[18]
Tralokinumab	DM6ENSJ	Approved	Monoclonal antibody	[19]
Upadacitinib	DM32B5U	Approved	NA	[15]
Vedolizmab	DMV3YMX	Approved	Monoclonal antibody	[4]

This Disease is Treated as An Indication in 60 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AG-SPT201	DMJRQDG	Phase 3	NA	[20]
AJM-300	DM5K6J4	Phase 3	NA	[21]
Alicaforsen	DMQ509J	Phase 3	Antisense drug	[22]
Brazikumab	DM4NWPE	Phase 3	Monoclonal antibody	[23]
DIMS-0150	DM19CFZ	Phase 3	Antisense drug	[24]
Entyvio	DMZVI9V	Phase 3	NA	[15]
Etrolizumab	DMR87TR	Phase 3	NA	[15]
GED-0301	DMTUV7L	Phase 3	NA	[15]
GS-5745	DMP8MDW	Phase 3	NA	[15]
LP-02	DMKXG9Y	Phase 3	NA	[25]
Pentasa Sachet	DMB5PBV	Phase 3	NA	[15]
Rhumab Beta7	DMGOTK4	Phase 3	Antibody	[26]
SB2	DMS1PFA	Phase 3	NA	[15]
SHP647	DMEWRXA	Phase 3	NA	[27]
SHR0302	DMUL8ZT	Phase 3	Small molecule	[28]
Sivelestat	DM6BZCV	Phase 3	Small molecular drug	[15]
ADS024	DMPP2GM	Phase 2	Live biotherapeutic	[29]
Alkaline Phosphatase	DMCPE4J	Phase 2	NA	[30]
AMG-181	DMODJTX	Phase 2	Antibody	[15]
Amiselimod	DMI7CYZ	Phase 2	Small molecule	[31]
AMT-101	DMB1645	Phase 2	Fusion protein	[32]
Anrukinzumab	DMTG2O0	Phase 2	Monoclonal antibody	[33]
Anti-IP10	DMVRNAO	Phase 2	Antibody	[34]
ASP-3291	DMBADQV	Phase 2	NA	[35]
Bertilimumab	DMRC0EQ	Phase 2	Monoclonal antibody	[15]
CBP-307	DM3TH6Y	Phase 2	Small molecule	[36]
Eclitasertib	DM2O8VW	Phase 2	Small molecule	[37]
Efavaleukin alfa	DMG77O2	Phase 2	Fusion Protein	[38]
GSK2982772	DM7HNFV	Phase 2	NA	[15]
JNJ 63723283	DMBXWJ5	Phase 2	Monoclonal antibody	[39]
JNJ-78934804	DMBGQPK	Phase 2	NA	[40]
KHK4083	DM7IDMT	Phase 2	NA	[15]
LY3074828	DMMR0L2	Phase 2	NA	[15]
LYC-30937	DMP05GL	Phase 2	NA	[15]
LYS006	DMI17QR	Phase 2	Small molecule	[41]
MORF-057	DMS274E	Phase 2	Small molecule	[42]
NX-13	DMLIAA7	Phase 2	Small molecule	[43]
Omilancor	DM595I9	Phase 2	Small molecule	[44]
PL8177	DML5V22	Phase 2	Small molecule	[45]
PN-943	DMUZLKW	Phase 2	peptide	[46]
PRA023	DMUY4VV	Phase 2	Antibody	[47]
RG7880	DM452RF	Phase 2	NA	[15]
S-0509	DM4KWEF	Phase 2	NA	[48]
SCH-527123	DMPUAOE	Phase 2	Small molecular drug	[49]
SP-333	DM2UKJV	Phase 2	NA	[50]
SPH3127	DMYL6RA	Phase 2	Small molecule	[51]
VTX-002	DMZ8Z5A	Phase 2	Small molecule	[52]
ADS051	DM2L6TX	Phase 1	Small molecule	[53]
AVX-470	DMAKD0I	Phase 1	Antibody	[15]
CCX507	DMO7TES	Phase 1	NA	[15]
INN-108	DMAY0CG	Phase 1	NA	[15]
MK-6194	DMN2MUG	Phase 1	NA	[54]
ONS-3010	DMVMZ8M	Phase 1	NA	[15]
PTG-100	DMQNRGE	Phase 1	NA	[15]
SAR252067	DM1OZ7O	Phase 1	NA	[55]
SER-287	DMYJ5TZ	Phase 1	NA	[15]
TAK-114	DMTXE19	Phase 1	NA	[56]
TD-1473	DMJG7AY	Phase 1	NA	[15]
AT-177	DMJ02RH	Clinical trial	Small molecule	[57]
PF-4708671	DMO0892	Clinical trial	Small molecular drug	[58]

This Disease is Treated as An Indication in 188 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alkyl mannoside derivative 1	DMW57UB	Patented	Small molecular drug	[59]
Alkyl mannoside derivative 10	DMHD51F	Patented	Carbohydrates	[59]
Alkyl mannoside derivative 11	DMMNZ2U	Patented	Carbohydrates	[59]
Alkyl mannoside derivative 12	DMX1OZF	Patented	Carbohydrates	[59]
Alkyl mannoside derivative 2	DMNQUKP	Patented	Small molecular drug	[59]
Alkyl mannoside derivative 3	DML2B58	Patented	Carbohydrates	[59]
Alkyl mannoside derivative 4	DMZR71O	Patented	Carbohydrates	[59]
Alkyl mannoside derivative 5	DM04ZJ2	Patented	Carbohydrates	[59]
Alkyl mannoside derivative 6	DMCIV32	Patented	Carbohydrates	[59]
Alkyl mannoside derivative 7	DMBLSH1	Patented	Carbohydrates	[59]
Alkyl mannoside derivative 8	DMZP1JT	Patented	Carbohydrates	[59]
Alkyl mannoside derivative 9	DMV1QUX	Patented	Carbohydrates	[59]
Aryl mannoside derivative 1	DM1TV6F	Patented	Carbohydrates	[59]
Aryl mannoside derivative 10	DM251GL	Patented	Carbohydrates	[59]
Aryl mannoside derivative 11	DMRVIPL	Patented	Carbohydrates	[59]
Aryl mannoside derivative 12	DMOG8XT	Patented	Carbohydrates	[59]
Aryl mannoside derivative 13	DM2W7JE	Patented	Carbohydrates	[59]
Aryl mannoside derivative 14	DMR648Z	Patented	Carbohydrates	[59]
Aryl mannoside derivative 15	DMQS8CF	Patented	Carbohydrates	[59]
Aryl mannoside derivative 16	DMP6QEC	Patented	Carbohydrates	[59]
Aryl mannoside derivative 17	DM0FSPQ	Patented	Carbohydrates	[59]
Aryl mannoside derivative 18	DM0YUBR	Patented	Carbohydrates	[59]
Aryl mannoside derivative 19	DM6K29H	Patented	Carbohydrates	[59]
Aryl mannoside derivative 2	DM4S2U5	Patented	Carbohydrates	[59]
Aryl mannoside derivative 20	DMZ2RV3	Patented	Carbohydrates	[59]
Aryl mannoside derivative 21	DMJBY68	Patented	Carbohydrates	[59]
Aryl mannoside derivative 22	DMJFDNB	Patented	Carbohydrates	[59]
Aryl mannoside derivative 23	DMWUNRV	Patented	Carbohydrates	[59]
Aryl mannoside derivative 3	DMF5XU8	Patented	Carbohydrates	[59]
Aryl mannoside derivative 4	DMO19Y6	Patented	Carbohydrates	[59]
Aryl mannoside derivative 5	DMMC31R	Patented	Carbohydrates	[59]
Aryl mannoside derivative 6	DM5MIEC	Patented	Carbohydrates	[59]
Aryl mannoside derivative 7	DM9YS40	Patented	Carbohydrates	[59]
Aryl mannoside derivative 8	DMK6PFQ	Patented	Carbohydrates	[59]
Aryl mannoside derivative 9	DMNSK7U	Patented	Carbohydrates	[59]
Beta-cyclodextrin conjugate derivative 1	DMZKTHL	Patented	Carbohydrates	[59]
Beta-cyclodextrin conjugate derivative 2	DM9W1FO	Patented	Carbohydrates	[59]
Beta-cyclodextrin conjugate derivative 3	DMQJF4P	Patented	Carbohydrates	[59]
Beta-cyclodextrin conjugate derivative 4	DMO9RE8	Patented	Carbohydrates	[59]
Beta-cyclodextrin conjugate derivative 5	DML2B7G	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 1	DMX6YGS	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 10	DMPF37N	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 11	DMKES0G	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 12	DM5T29W	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 13	DM1Y8OM	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 14	DM4C5QY	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 15	DMKXT7H	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 16	DMP9742	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 17	DMIXV6G	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 18	DMHOPE0	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 19	DME8DQ0	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 2	DMMB60X	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 20	DMNC5S0	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 21	DMGSLHN	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 22	DMYLVB3	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 23	DM2YVGH	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 24	DMF5TB4	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 25	DMRM3E9	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 26	DMYXLCJ	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 27	DMTDPHY	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 28	DMSNMZ2	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 29	DMCLTY3	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 3	DMAITK3	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 30	DMPLAWQ	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 31	DMMPJ3E	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 4	DMVF63N	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 5	DMRS1WG	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 6	DMEWA7U	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 7	DMD7053	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 8	DMWF2VG	Patented	Carbohydrates	[59]
Biaryl mannoside derivative 9	DM1Q7AL	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 1	DMS5UFX	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 10	DMITLPW	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 11	DMZF5XI	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 12	DMU0YST	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 13	DM83LTH	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 14	DMMRTWG	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 15	DM97BIQ	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 16	DMECZVG	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 17	DM7L8T5	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 18	DM2GZ5Y	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 19	DMGA0R6	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 2	DMQB4DR	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 20	DMDIYJ1	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 21	DMTR6BX	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 22	DMQGFKY	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 23	DMC8OVU	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 24	DMLUZ3K	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 25	DMBWQ8L	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 26	DM5Q4T2	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 27	DMWQ6FJ	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 28	DMMOTWK	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 29	DM9H0Q3	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 3	DMOKJEP	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 30	DM81RIY	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 4	DM0VR23	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 5	DMOS03R	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 6	DM93VEB	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 7	DM46NRV	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 8	DMZCWM5	Patented	Carbohydrates	[59]
Biphenyl mannoside derivative 9	DMP52HJ	Patented	Carbohydrates	[59]
C-linked disaccharide biphenyl mannoside derivative 1	DMV6H95	Patented	Carbohydrates	[59]
C-linked disaccharide biphenyl mannoside derivative 2	DMJT1WG	Patented	Carbohydrates	[59]
C-linked disaccharide biphenyl mannoside derivative 3	DMY10T2	Patented	Carbohydrates	[59]
C-linked disaccharide biphenyl mannoside derivative 4	DMRLE65	Patented	Carbohydrates	[59]
C-linked disaccharide biphenyl mannoside derivative 5	DMUG7E9	Patented	Carbohydrates	[59]
C-linked disaccharide biphenyl mannoside derivative 6	DMUILMD	Patented	Carbohydrates	[59]
Mannoside derivative 1	DMIE7U3	Patented	Carbohydrates	[59]
Mannoside derivative 10	DMZYRHN	Patented	Carbohydrates	[59]
Mannoside derivative 11	DM8I051	Patented	Carbohydrates	[59]
Mannoside derivative 12	DM4QUY0	Patented	Carbohydrates	[59]
Mannoside derivative 13	DM0U7P9	Patented	Carbohydrates	[59]
Mannoside derivative 2	DMFEQD2	Patented	Carbohydrates	[59]
Mannoside derivative 3	DMPF2UG	Patented	Carbohydrates	[59]
Mannoside derivative 4	DMZBY73	Patented	Carbohydrates	[59]
Mannoside derivative 5	DMMXNY8	Patented	Carbohydrates	[59]
Mannoside derivative 6	DMCM3NW	Patented	Carbohydrates	[59]
Mannoside derivative 7	DMOUT1F	Patented	Carbohydrates	[59]
Mannoside derivative 8	DMKTJAH	Patented	Carbohydrates	[59]
Mannoside derivative 9	DMIKZXD	Patented	Carbohydrates	[59]
PMID26651364-Compound-105	DMOJVK6	Patented	Carbohydrates	[59]
PMID26651364-Compound-106	DMQZJDF	Patented	Carbohydrates	[59]
PMID26651364-Compound-107	DMMZ1WL	Patented	Carbohydrates	[59]
PMID26651364-Compound-108	DMA7D3K	Patented	Carbohydrates	[59]
PMID26651364-Compound-109	DM01IWV	Patented	Carbohydrates	[59]
PMID26651364-Compound-10a	DMTPBNY	Patented	Carbohydrates	[59]
PMID26651364-Compound-10b	DM16ANH	Patented	Carbohydrates	[59]
PMID26651364-Compound-10c	DMCRNWA	Patented	Carbohydrates	[59]
PMID26651364-Compound-10d	DMGIV3C	Patented	Carbohydrates	[59]
PMID26651364-Compound-110	DMPA3IX	Patented	Carbohydrates	[59]
PMID26651364-Compound-111	DMY9R58	Patented	Carbohydrates	[59]
PMID26651364-Compound-112	DM1LIRP	Patented	Carbohydrates	[59]
PMID26651364-Compound-113	DM6OQKM	Patented	Carbohydrates	[59]
PMID26651364-Compound-114	DM5GHJA	Patented	Carbohydrates	[59]
PMID26651364-Compound-115	DMHIA26	Patented	Carbohydrates	[59]
PMID26651364-Compound-116	DMJ3201	Patented	Carbohydrates	[59]
PMID26651364-Compound-117a	DM6LXHS	Patented	Carbohydrates	[59]
PMID26651364-Compound-117b	DMUQSM1	Patented	Carbohydrates	[59]
PMID26651364-Compound-118	DM6ZRV4	Patented	Carbohydrates	[59]
PMID26651364-Compound-119	DMONAZI	Patented	Carbohydrates	[59]
PMID26651364-Compound-11b	DMGBFK3	Patented	Carbohydrates	[59]
PMID26651364-Compound-11c	DM76WBP	Patented	Carbohydrates	[59]
PMID26651364-Compound-120	DMZTBEQ	Patented	Carbohydrates	[59]
PMID26651364-Compound-121	DM4ZG0Q	Patented	Carbohydrates	[59]
PMID26651364-Compound-122	DMVFTIL	Patented	Carbohydrates	[59]
PMID26651364-Compound-123	DMR0E5W	Patented	Carbohydrates	[59]
PMID26651364-Compound-124	DM6VER5	Patented	Carbohydrates	[59]
PMID26651364-Compound-125	DMINUDB	Patented	Carbohydrates	[59]
PMID26651364-Compound-126a	DMSTKH6	Patented	Carbohydrates	[59]
PMID26651364-Compound-126b	DM2I1QZ	Patented	Carbohydrates	[59]
PMID26651364-Compound-126c	DM80PI1	Patented	Carbohydrates	[59]
PMID26651364-Compound-127	DMEN8RA	Patented	Carbohydrates	[59]
PMID26651364-Compound-128	DM4W0BX	Patented	Carbohydrates	[59]
PMID26651364-Compound-4	DMY0HP1	Patented	Carbohydrates	[59]
PMID26651364-Compound-45	DMLBZGO	Patented	Carbohydrates	[59]
PMID26651364-Compound-46	DMQFDU8	Patented	Carbohydrates	[59]
PMID26651364-Compound-47	DM4S5PB	Patented	Carbohydrates	[59]
PMID26651364-Compound-48	DMHXFGU	Patented	Carbohydrates	[59]
PMID26651364-Compound-49	DMMV5A9	Patented	Carbohydrates	[59]
PMID26651364-Compound-5	DMH7XL3	Patented	Carbohydrates	[59]
PMID26651364-Compound-50	DM6GFYR	Patented	Carbohydrates	[59]
PMID26651364-Compound-5a	DM01GVE	Patented	Carbohydrates	[59]
PMID26651364-Compound-5b	DMLHJ1E	Patented	Carbohydrates	[59]
PMID26651364-Compound-5c	DMDQTA2	Patented	Carbohydrates	[59]
PMID26651364-Compound-5d	DMF6Z5I	Patented	Carbohydrates	[59]
PMID26651364-Compound-5e	DM9TJR5	Patented	Carbohydrates	[59]
PMID26651364-Compound-5f	DMAZIY6	Patented	Carbohydrates	[59]
PMID26651364-Compound-5g	DMSW0HB	Patented	Carbohydrates	[59]
PMID26651364-Compound-6a	DM8HAJ3	Patented	Carbohydrates	[59]
PMID26651364-Compound-6b	DMBINOJ	Patented	Carbohydrates	[59]
PMID26651364-Compound-6c	DMPF86L	Patented	Carbohydrates	[59]
PMID26651364-Compound-6d	DM9J57W	Patented	Carbohydrates	[59]
PMID26651364-Compound-6e	DM4LF0X	Patented	Carbohydrates	[59]
PMID26651364-Compound-7a	DMQMBY9	Patented	Carbohydrates	[59]
PMID26651364-Compound-7b	DM3LCIM	Patented	Carbohydrates	[59]
PMID26651364-Compound-7c	DMGCUJB	Patented	Carbohydrates	[59]
PMID26651364-Compound-7d	DM89VQT	Patented	Carbohydrates	[59]
PMID26651364-Compound-7e	DM2SZ0B	Patented	Carbohydrates	[59]
PMID26651364-Compound-8a	DM1M3WF	Patented	Carbohydrates	[59]
PMID26651364-Compound-8b	DMYVU36	Patented	Carbohydrates	[59]
PMID26651364-Compound-8c	DME7UNT	Patented	Carbohydrates	[59]
PMID26651364-Compound-8d	DMSO2F8	Patented	Carbohydrates	[59]
PMID26651364-Compound-9a	DMAXWPS	Patented	Carbohydrates	[59]
PMID26651364-Compound-9b	DM6HTU0	Patented	Carbohydrates	[59]
PMID26651364-Compound-9c	DM49V8G	Patented	Carbohydrates	[59]
PMID26651364-Compound-9d	DMF0L3E	Patented	Carbohydrates	[59]
PMID26651364-Compound-9e	DM9FIKD	Patented	Carbohydrates	[59]
PMID26651364-Compound-9f	DMF1MV6	Patented	Carbohydrates	[59]

This Disease is Treated as An Indication in 5 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
LEMINOPRAZOLE	DMBKNJT	Discontinued in Preregistration	Small molecular drug	[60]
Deligoparin sodium	DMXKWAL	Discontinued in Phase 3	NA	[61]
Pibutidine	DMXSTRM	Discontinued in Phase 3	Small molecular drug	[62]
AG-041R	DM625LN	Terminated	Small molecular drug	[63]
KSB-304	DMPMTZD	Terminated	NA	[64]

This Disease is Treated as An Indication in 8 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AP-005	DMMYP33	Investigative	NA	[65]
ASP-2002	DM3XCM1	Investigative	NA	[66]
GP-1200	DMHPI0I	Investigative	NA	[65]
KAG-308	DMN4EUB	Investigative	NA	[67]
KPPF-1	DMEVEW2	Investigative	NA	[65]
OPC-22575	DMO4WH9	Investigative	NA	[68]
P-2281	DMZI8QW	Investigative	NA	[69]
Recombinant human alkaline phosphatase	DMFC953	Investigative	NA	[65]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 296 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ANTXR2	TTOD34I	Limited	Genetic Variation	[70]
APEH	TTYWEDQ	Limited	Genetic Variation	[71]
ATXN2	TTPQJ7P	Limited	Genetic Variation	[70]
CAMP	TTULOB6	Limited	Biomarker	[72]
CD14	TT6I7DC	Limited	Biomarker	[73]
CD24	TTCTYNP	Limited	Genetic Variation	[74]
CD6	TTMF6KC	Limited	Genetic Variation	[70]
CD80	TT89Z17	Limited	Altered Expression	[75]
CX3CL1	TT1OFBQ	Limited	Biomarker	[76]
CYP21A2	TTP4GLG	Limited	Genetic Variation	[77]
EBI3	TTJF68X	Limited	Genetic Variation	[78]
ERAP1	TT60XFL	Limited	Genetic Variation	[70]
ERAP2	TTVGS1C	Limited	Genetic Variation	[70]
ERN1	TTKIAT3	Limited	Genetic Variation	[70]
GNAO1	TTAXD8Z	Limited	Biomarker	[79]
HDAC7	TTMUEK1	Limited	Genetic Variation	[80]
HLA-DQB2	TTL7VOU	Limited	Biomarker	[79]
IL17A	TTG0MT6	Limited	Altered Expression	[73]
IL17D	TTC5LTG	Limited	Genetic Variation	[81]
IL2	TTF89GD	Limited	Biomarker	[82]
IL23A	TTC1GLB	Limited	Biomarker	[83]
IL33	TT5MD4P	Limited	Altered Expression	[84]
IL4	TTLGTKB	Limited	Altered Expression	[85]
IL7	TT8FRMO	Limited	Biomarker	[86]
IL9	TT0JTFD	Limited	Biomarker	[87]
IRAK3	TTBPJOK	Limited	Biomarker	[88]
JAK1	TT6DM01	Limited	Biomarker	[89]
KCNN1	TT9R6BE	Limited	Biomarker	[90]
KEAP1	TT3Z6Y9	Limited	Genetic Variation	[70]
KLK1	TT5T3P6	Limited	Biomarker	[91]
KSR1	TTHL1TV	Limited	Genetic Variation	[70]
LCN2	TTKTLAI	Limited	Biomarker	[92]
LCT	TTA0OSE	Limited	Genetic Variation	[93]
LRP6	TTSXOWE	Limited	Altered Expression	[94]
LRRK2	TTK0FEA	Limited	Genetic Variation	[70]
LYZ	TTAOZBW	Limited	Genetic Variation	[95]
MMP7	TTMTWOS	Limited	Altered Expression	[96]
MYD88	TTB6Q2O	Limited	Biomarker	[97]
NEDD9	TT1UREA	Limited	Biomarker	[98]
NOD1	TTYSRXM	Limited	Genetic Variation	[99]
NPEPPS	TT371QC	Limited	Genetic Variation	[70]
NR0B1	TTTK36V	Limited	Altered Expression	[100]
NR1I2	TT7LCTF	Limited	Genetic Variation	[101]
NTF3	TTZHKV9	Limited	Biomarker	[90]
OSMR	TTAH0KM	Limited	Genetic Variation	[70]
PGA5	TTKZ864	Limited	Genetic Variation	[102]
PLA2G2A	TTO8QRU	Limited	Altered Expression	[103]
PRKCB	TTYPXQF	Limited	Genetic Variation	[80]
PRKCQ	TT1MS7X	Limited	Genetic Variation	[70]
PTGER4	TT79WV3	Limited	Genetic Variation	[104]
PTGIR	TTOFYT1	Limited	Genetic Variation	[105]
PTPRC	TTUS45N	Limited	Genetic Variation	[77]
RIC8B	TT26BHC	Limited	Genetic Variation	[70]
RPS6KB1	TTG0U4H	Limited	Genetic Variation	[70]
SELL	TT2IYXF	Limited	Genetic Variation	[106]
SFTPD	TTGLMU7	Limited	Altered Expression	[107]
SH2B3	TT36N7Z	Limited	Genetic Variation	[70]
TACR1	TTZPO1L	Limited	Altered Expression	[108]
TACR2	TTYO0A3	Limited	Altered Expression	[109]
TLR9	TTSHG0T	Limited	Altered Expression	[110]
TSLP	TTHMW3T	Limited	Altered Expression	[111]
VIP	TTGTWLF	Limited	Biomarker	[112]
APOA4	TTNC3WS	Disputed	Altered Expression	[113]
CD209	TTBXIM9	Disputed	Biomarker	[114]
F11R	TT3C8EG	Disputed	Altered Expression	[115]
IL21	TT9QEJ6	Disputed	Biomarker	[116]
MBL2	TTMQDZ5	Disputed	Altered Expression	[117]
MLH1	TTISG27	Disputed	Genetic Variation	[118]
VIPR1	TTCL30I	Disputed	Altered Expression	[119]
ADRB2	TTG8ZWP	moderate	Biomarker	[120]
BRD2	TTDP48B	moderate	Genetic Variation	[121]
CCR9	TTIPS8B	moderate	Biomarker	[122]
CIT	TT3BKTU	moderate	Genetic Variation	[123]
CXCR1	TTMWT8Z	moderate	Biomarker	[71]
DAG1	TT4X7PG	moderate	Genetic Variation	[124]
FASLG	TTO7014	moderate	Therapeutic	[125]
GHRL	TT1OCL0	moderate	Biomarker	[126]
GPR18	TTSLJAR	moderate	Genetic Variation	[123]
IL7R	TTAWI51	moderate	Biomarker	[127]
LTF	TTSZDQU	moderate	Therapeutic	[128]
MMP1	TTMX39J	moderate	Genetic Variation	[129]
MMP10	TTXLEG7	moderate	Altered Expression	[96]
NFKBIA	TTSHAEB	moderate	Genetic Variation	[130]
PLA2G1B	TT9V5JH	moderate	Genetic Variation	[95]
PRTN3	TT5MLC4	moderate	Biomarker	[131]
REG4	TTVZEHU	moderate	Altered Expression	[132]
SLC3A2	TT5CZSM	moderate	Altered Expression	[133]
SOCS1	TT8COJM	moderate	Biomarker	[88]
AADAT	TTT3IXG	Strong	Altered Expression	[134]
ABCG5	TTKZ7WY	Strong	Altered Expression	[84]
ADORA2A	TTM2AOE	Strong	Altered Expression	[135]
ADORA3	TTJFY5U	Strong	Altered Expression	[136]
ADRA2A	TTWG9A4	Strong	Genetic Variation	[137]
AHR	TT037IE	Strong	Biomarker	[138]
ALPI	TTHYMUV	Strong	Altered Expression	[139]
AMACR	TTLN1AP	Strong	Biomarker	[140]
AOC1	TTM3B5R	Strong	Genetic Variation	[141]
APOH	TT2OUI9	Strong	Altered Expression	[142]
ARRB2	TT8SO2I	Strong	Biomarker	[143]
BIRC2	TTQ5LRD	Strong	Biomarker	[144]
BIRC3	TTAIWZN	Strong	Altered Expression	[144]
CA1	TTHQPL7	Strong	Biomarker	[145]
CA2	TTANPDJ	Strong	Biomarker	[146]
CASP3	TTPF2QI	Strong	Biomarker	[147]
CBR1	TTVG0SN	Strong	Biomarker	[148]
CCL20	TT2XAZY	Strong	Genetic Variation	[80]
CCL21	TTLZK1U	Strong	Biomarker	[149]
CCL3	TT8I4WB	Strong	Altered Expression	[150]
CCR1	TTC24WT	Strong	Altered Expression	[151]
CCR6	TTFDB30	Strong	Altered Expression	[152]
CD160	TTOFEAS	Strong	Biomarker	[153]
CD1A	TTBGTFN	Strong	Biomarker	[154]
CD28	TTQ13FT	Strong	Biomarker	[155]
CD33	TTJVYO3	Strong	Biomarker	[156]
CD37	TTFCW29	Strong	Biomarker	[157]
CD55	TT5Z9WY	Strong	Altered Expression	[158]
CD86	TT53XHB	Strong	Altered Expression	[159]
CDH1	TTLAWO6	Strong	Biomarker	[160]
CDH11	TTRGWZC	Strong	Altered Expression	[161]
CDH3	TTARMD9	Strong	Genetic Variation	[71]
CEACAM5	TTY6DTE	Strong	Biomarker	[162]
CFB	TTA0P7K	Strong	Genetic Variation	[163]
CHST15	TTFK7E1	Strong	Biomarker	[164]
CLCN2	TT30NW6	Strong	Altered Expression	[165]
CLDN18	TT6PKBX	Strong	Altered Expression	[166]
COL18A1	TT63DI9	Strong	Altered Expression	[167]
CRHR1	TT7EFHR	Strong	Biomarker	[168]
CRHR2	TTIY658	Strong	Altered Expression	[169]
CSNK1E	TTA8PLI	Strong	Biomarker	[170]
CTF1	TTXGTZU	Strong	Biomarker	[171]
CXCL8	TTCTE1G	Strong	Altered Expression	[73]
CXCR2	TT30C9G	Strong	Biomarker	[71]
CXCR6	TT2BVUA	Strong	Biomarker	[172]
CYP2C19	TTZ58XG	Strong	Altered Expression	[173]
CYP3A5	TTHS0OK	Strong	Biomarker	[174]
DAO	TT7Y3EJ	Strong	Altered Expression	[175]
DDIT4	TTVEOY6	Strong	Biomarker	[176]
DNAJB1	TTPXAWS	Strong	Altered Expression	[177]
DNMT3A	TTJUALD	Strong	Biomarker	[178]
DPEP1	TTYUENF	Strong	Biomarker	[179]
EED	TTFNJ4R	Strong	Biomarker	[180]
EGLN2	TTMHFRY	Strong	Biomarker	[181]
ETS1	TTTGPSD	Strong	Genetic Variation	[70]
F12	TTRJSMV	Strong	Altered Expression	[182]
F2RL1	TTQR74A	Strong	Biomarker	[183]
F5	TT1O264	Strong	Genetic Variation	[184]
FABP2	TTS4YLO	Strong	Biomarker	[185]
FAS	TT7LTUJ	Strong	Therapeutic	[125]
FCAR	TTGUJAO	Strong	Biomarker	[186]
FCGR1A	TTZK4I3	Strong	Biomarker	[187]
FCGR2A	TTXT21W	Strong	Biomarker	[188]
FFAR2	TT0FYAN	Strong	Altered Expression	[189]
FGF7	TTFY134	Strong	Biomarker	[190]
FKBP15	TT1XEQO	Strong	Biomarker	[191]
FPR2	TTOJ1NF	Strong	Biomarker	[192]
FUT3	TTUPAD7	Strong	Genetic Variation	[193]
GPR12	TT3IPW2	Strong	Genetic Variation	[194]
GPR183	TTME5YJ	Strong	Altered Expression	[195]
GPR35	TT254XD	Strong	Genetic Variation	[196]
GPR55	TTNET8J	Strong	Altered Expression	[197]
GUCY2C	TTLDPRG	Strong	Altered Expression	[198]
HCRTR1	TT60Q8D	Strong	Altered Expression	[199]
HDAC11	TT8K17W	Strong	Biomarker	[200]
HLA-G	TTLKFB3	Strong	Altered Expression	[201]
HNF4A	TT2F3CD	Strong	Altered Expression	[202]
HNMT	TT2B6EV	Strong	Genetic Variation	[141]
HSP90B1	TTFPKXQ	Strong	Biomarker	[203]
HTR3A	TTPC4TU	Strong	Altered Expression	[204]
HTR7	TTO9X1H	Strong	Altered Expression	[204]
HTRA1	TT8POQR	Strong	Altered Expression	[205]
ICOSLG	TTB9Z8R	Strong	Genetic Variation	[206]
IFNGR2	TT13TL0	Strong	Genetic Variation	[207]
IL10RB	TTJTRMK	Strong	Genetic Variation	[208]
IL11	TTGUYTR	Strong	Biomarker	[209]
IL12B	TTGW72V	Strong	Biomarker	[210]
IL13RA2	TTMPZ7V	Strong	Altered Expression	[211]
IL15RA	TTGN89I	Strong	Altered Expression	[212]
IL16	TTW4R0B	Strong	Altered Expression	[213]
IL18RAP	TTZUJVE	Strong	Biomarker	[214]
IL19	TT87RWS	Strong	Biomarker	[215]
IL1R1	TTWOTEA	Strong	Genetic Variation	[70]
IL1RL1	TT4GZA4	Strong	Biomarker	[216]
IL1RL2	TTUS18T	Strong	Biomarker	[217]
IL20	TTNZMY2	Strong	Genetic Variation	[218]
IL24	TT1EPXZ	Strong	Biomarker	[219]
IL2RA	TT10Y9E	Strong	Biomarker	[220]
IL5	TTPREZD	Strong	Altered Expression	[221]
INPP5D	TTTP2Z1	Strong	Altered Expression	[222]
IRAK1	TTXAJWN	Strong	Biomarker	[223]
ITCH	TT5SEWD	Strong	Altered Expression	[224]
ITGAE	TTH0Z37	Strong	Biomarker	[225]
ITGAL	TT48WR6	Strong	Genetic Variation	[70]
ITGAV	TTT1R2L	Strong	Biomarker	[226]
ITGB1	TTBVIQC	Strong	Genetic Variation	[227]
JAK2	TTRMX3V	Strong	Genetic Variation	[207]
KCNQ2	TTPXI3S	Strong	Biomarker	[104]
KIR2DL1	TT4UXPE	Strong	Genetic Variation	[228]
KIR2DL2	TTU0P73	Strong	Biomarker	[229]
KLRK1	TTLRN4A	Strong	Biomarker	[230]
LAIR1	TTSI7A8	Strong	Biomarker	[231]
LANCL1	TTZW8NS	Strong	Biomarker	[87]
LANCL2	TTMK3EX	Strong	Biomarker	[232]
LILRB4	TTREOKA	Strong	Biomarker	[159]
LY96	TT8S9AV	Strong	Genetic Variation	[130]
LYN	TT1RWNJ	Strong	Altered Expression	[233]
MAGEC2	TTKGUEB	Strong	Biomarker	[234]
MAP2K2	TT8H9GB	Strong	Altered Expression	[235]
MAP3K14	TT4LIAC	Strong	Genetic Variation	[236]
MAP3K8	TTGECUM	Strong	Biomarker	[237]
MASP2	TTR01E9	Strong	Biomarker	[238]
MAZ	TT059DA	Strong	Altered Expression	[239]
MBTPS1	TTNSM2I	Strong	Biomarker	[172]
MIF	TT6804T	Strong	Genetic Variation	[240]
MKNK2	TTRECN3	Strong	Altered Expression	[241]
MMP9	TT6X50U	Strong	Altered Expression	[92]
MPO	TTVCZPI	Strong	Altered Expression	[85]
MSH2	TTCAWRT	Strong	Genetic Variation	[242]
MSI1	TTSM4BA	Strong	Biomarker	[243]
MST1R	TTBQ3OC	Strong	Genetic Variation	[244]
MUC17	TTVO0JU	Strong	Genetic Variation	[245]
MUC5AC	TTEL90S	Strong	Altered Expression	[246]
NAAA	TTMN4HY	Strong	Biomarker	[247]
NEK6	TT8I2M7	Strong	Genetic Variation	[248]
NELL1	TT7H4BF	Strong	Biomarker	[249]
NPR1	TTM9IYA	Strong	Biomarker	[250]
NPSR1	TTV1C0Z	Strong	Genetic Variation	[251]
NR5A2	TTAU3SY	Strong	Genetic Variation	[80]
ODC1	TTUMGNO	Strong	Altered Expression	[252]
PCYT1B	TTUAIKM	Strong	Biomarker	[253]
PGD	TTZ3IFB	Strong	Biomarker	[254]
PLA2G7	TTDNFMT	Strong	Biomarker	[255]
PLK2	TT976FS	Strong	Biomarker	[234]
PREP	TTNGKET	Strong	Altered Expression	[256]
PTGS1	TT8NGED	Strong	Biomarker	[257]
PTPN2	TTY8PUS	Strong	Genetic Variation	[258]
PTPRS	TTCWXFA	Strong	Biomarker	[259]
REL	TT1ZCTH	Strong	Altered Expression	[260]
RIPK1	TTVJHX8	Strong	Biomarker	[261]
RPGR	TTHBDA9	Strong	Genetic Variation	[262]
RPSA	TTLUW5B	Strong	Biomarker	[87]
S1PR1	TT9JZCK	Strong	Biomarker	[263]
S1PR5	TTDZCKV	Strong	Biomarker	[263]
SDC1	TTYDSVG	Strong	Biomarker	[264]
SELPLG	TTS5K8U	Strong	Altered Expression	[265]
SLC11A2	TT2IS7P	Strong	Biomarker	[266]
SLC15A1	TT5LF3C	Strong	Biomarker	[267]
SLC1A5	TTF7WRM	Strong	Altered Expression	[268]
SLC23A1	TT6XAGK	Strong	Genetic Variation	[269]
SLC40A1	TT6Y1PG	Strong	Biomarker	[266]
SLC44A4	TT0NYDG	Strong	Biomarker	[270]
SLC6A14	TTB6H2S	Strong	Biomarker	[271]
SLC6A4	TT3ROYC	Strong	Genetic Variation	[272]
SLC9A1	TTGSEFH	Strong	Altered Expression	[273]
SLC9A3	TTFZVPO	Strong	Biomarker	[274]
SMAD3	TTHQZV7	Strong	Genetic Variation	[275]
SOCS3	TTI0ME6	Strong	Biomarker	[276]
SPN	TTOZAX0	Strong	Genetic Variation	[277]
STAT3	TTHJT3X	Strong	Biomarker	[278]
STK38	TT27XFN	Strong	Altered Expression	[279]
STK39	TTYQTIU	Strong	Biomarker	[280]
SUCNR1	TT4FX9Y	Strong	Biomarker	[281]
TAAR1	TTIU98M	Strong	Biomarker	[282]
TBX21	TTNF9PH	Strong	Genetic Variation	[207]
TBXAS1	TTKNWZ4	Strong	Biomarker	[283]
TLR1	TTW14D0	Strong	Genetic Variation	[284]
TLR3	TTD24Y0	Strong	Genetic Variation	[285]
TLR8	TT8CWFK	Strong	Altered Expression	[286]
TM6SF2	TTE1OHM	Strong	Genetic Variation	[287]
TNFAIP3	TT5W0IO	Strong	Altered Expression	[224]
TNFRSF14	TTWGTC1	Strong	Genetic Variation	[70]
TNFRSF17	TTZ3P4W	Strong	Genetic Variation	[288]
TNFRSF1A	TTG043C	Strong	Biomarker	[289]
TNFRSF1B	TT63WSF	Strong	Genetic Variation	[290]
TNFSF13B	TTWMIDN	Strong	Altered Expression	[291]
TNK2	TTIET93	Strong	Altered Expression	[292]
TPH1	TTZSJHV	Strong	Altered Expression	[293]
TRPA1	TTELV3W	Strong	Altered Expression	[294]
TRPV1	TTMI6F5	Strong	Posttranslational Modification	[295]
TRPV2	TTBECWA	Strong	Altered Expression	[296]
TRPV3	TT946IA	Strong	Altered Expression	[296]
TYK2	TTBYWP2	Strong	Genetic Variation	[70]
ULK1	TT4D7MJ	Strong	Altered Expression	[297]
VCAM1	TTHCEF6	Strong	Biomarker	[298]
WAS	TTE8T73	Strong	Biomarker	[191]
WNK1	TTJ9UMX	Strong	Biomarker	[136]
ZAP70	TTUMHT8	Strong	Genetic Variation	[299]
CCR3	TTD3XFU	Definitive	Altered Expression	[300]
IL1R2	TT51DEV	Definitive	Biomarker	[301]
IL37	TTQTX98	Definitive	Biomarker	[83]
LPAR6	TTZDAGB	Definitive	Biomarker	[302]
MGLL	TTZ963I	Definitive	Biomarker	[303]
P2RY13	TT1FE3L	Definitive	Biomarker	[302]
P2RY14	TT72OKI	Definitive	Biomarker	[302]
RIPK2	TTCQ2E5	Definitive	Biomarker	[304]
SPHK1	TTOHFIY	Definitive	Biomarker	[305]
TERF2	TT5XSLT	Definitive	Biomarker	[306]

This Disease Is Related to 11 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC11A1	DT650XW	Limited	Genetic Variation	[307]
SLC39A11	DTEOAND	Limited	Genetic Variation	[80]
SLC9A8	DTNY0C2	Limited	Genetic Variation	[70]
SLC22A23	DTMJK12	Strong	Genetic Variation	[308]
SLC22A5	DT3HUVD	Strong	Genetic Variation	[309]
SLC25A20	DTQOUM4	Strong	Biomarker	[146]
SLC26A3	DTN1FMD	Strong	Genetic Variation	[310]
SLC35A1	DTVZIRG	Strong	Biomarker	[311]
SLC52A1	DT7NOKR	Strong	Biomarker	[312]
SLC5A8	DTE3TAW	Strong	Biomarker	[313]
SLCO6A1	DTIFXNS	Strong	Altered Expression	[314]

This Disease Is Related to 23 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
GSTM1	DEYZEJA	Limited	Genetic Variation	[315]
MT1A	DE5ME8A	Limited	Biomarker	[316]
PARK7	DEPOVCH	Limited	Genetic Variation	[80]
UGT1A7	DEZO4N3	Limited	Biomarker	[317]
NAT1	DE7OAB3	moderate	Genetic Variation	[318]
AKR1B10	DEP6GT1	Strong	Altered Expression	[319]
ASMT	DEHGR57	Strong	Altered Expression	[320]
CYP26B1	DEZT8FM	Strong	Biomarker	[321]
CYP2C18	DEZMWRE	Strong	Altered Expression	[173]
CYP4F3	DEFCMPI	Strong	Genetic Variation	[322]
CYP7B1	DE36TMY	Strong	Biomarker	[195]
EGLN3	DEMQTKH	Strong	Biomarker	[323]
FAAH	DEUM1EX	Strong	Biomarker	[247]
GALM	DE63NYG	Strong	Biomarker	[324]
HPGD	DEHKSC6	Strong	Biomarker	[325]
KYAT1	DES9MCU	Strong	Altered Expression	[134]
ME1	DE97WM8	Strong	Altered Expression	[326]
MTRR	DE6NIY9	Strong	Genetic Variation	[327]
NDUFS7	DEIW03B	Strong	Genetic Variation	[328]
PTGDS	DER3H9C	Strong	Biomarker	[283]
SMOX	DEOH5V3	Strong	Altered Expression	[329]
SULT1E1	DESTKG6	Strong	Biomarker	[330]
TPMT	DEFQ8VO	Strong	Genetic Variation	[331]

This Disease Is Related to 445 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACAD8	OT3JI5GB	Limited	Biomarker	[332]
ACTA2	OTEDLG8E	Limited	Genetic Variation	[70]
ADAD1	OTXRDF3Z	Limited	Genetic Variation	[71]
ADCY7	OTAWMGP3	Limited	Genetic Variation	[80]
AMZ1	OTDH9XM0	Limited	Genetic Variation	[80]
ANKRD55	OT62KZII	Limited	Genetic Variation	[70]
ASAP2	OTGEXULW	Limited	Genetic Variation	[70]
ASCC1	OTH4VAP9	Limited	Altered Expression	[333]
ATG5	OT4T5SMS	Limited	Genetic Variation	[70]
BANK1	OTXAAA11	Limited	Genetic Variation	[70]
C17orf67	OTCL5EE8	Limited	Genetic Variation	[70]
C1orf141	OTASPHL0	Limited	Genetic Variation	[70]
CAMK2A	OTJGX19T	Limited	Genetic Variation	[80]
CARD9	OTJ81AWD	Limited	Genetic Variation	[80]
CCHCR1	OT22C116	Limited	Genetic Variation	[334]
CD226	OT4UG0KB	Limited	Genetic Variation	[70]
CHP1	OTHTXN1A	Limited	Genetic Variation	[80]
CLDN1	OT27KV99	Limited	Biomarker	[335]
CLDN7	OTNE0XHQ	Limited	Biomarker	[335]
CLEC16A	OTLGV5SV	Limited	Genetic Variation	[70]
CMC1	OTCWYKPI	Limited	Genetic Variation	[70]
CPEB4	OTW1SCZW	Limited	Genetic Variation	[70]
CREM	OTJIJ5AL	Limited	Genetic Variation	[70]
DDX39A	OT0Z6E1K	Limited	Genetic Variation	[336]
DENND1B	OT3VCNPE	Limited	Genetic Variation	[70]
EEF1AKMT2	OTBZ5JQS	Limited	Genetic Variation	[80]
FAM118A	OT6EM97E	Limited	Genetic Variation	[70]
FAM177A1	OTXTA14N	Limited	Genetic Variation	[70]
FHL2	OT0OAYWT	Limited	Altered Expression	[337]
FIBP	OTI7131S	Limited	Genetic Variation	[70]
FNDC3A	OTUX3S2I	Limited	Genetic Variation	[70]
GABPA	OT9YB2SA	Limited	Biomarker	[338]
GAL3ST2	OTZT1PLE	Limited	Genetic Variation	[70]
GCKR	OTSIWXGG	Limited	Genetic Variation	[70]
GLYAT	OT3WWYXD	Limited	Genetic Variation	[70]
GNA12	OT3IRZH3	Limited	Genetic Variation	[80]
HIPK1	OTSEA8RS	Limited	Genetic Variation	[70]
HSPA1L	OTC2V1K6	Limited	Genetic Variation	[77]
IFIH1	OTZA2AHA	Limited	Genetic Variation	[70]
IL18BP	OTW0LRYZ	Limited	Altered Expression	[339]
IL27	OTIS3OF8	Limited	Genetic Variation	[81]
INAVA	OTGXNB86	Limited	Genetic Variation	[80]
ISG20	OTCWRJJW	Limited	Biomarker	[220]
JAZF1	OTXTYSYD	Limited	Genetic Variation	[70]
LGALS4	OTKQCG0H	Limited	Altered Expression	[340]
MAGI2	OTXDDKZS	Limited	Genetic Variation	[341]
MAML2	OT1TSVAR	Limited	Genetic Variation	[80]
MEFV	OTRJ6S6K	Limited	Genetic Variation	[342]
MNAT1	OTXLOYCB	Limited	Biomarker	[343]
MPZ	OTAR2YXH	Limited	Altered Expression	[100]
MSH5	OTDARQT3	Limited	Genetic Variation	[77]
MST1	OTOC4UNG	Limited	Genetic Variation	[80]
MUC2	OT3X4QVX	Limited	Biomarker	[221]
MYRF	OTKF6AEB	Limited	Genetic Variation	[70]
NDFIP1	OTIORSWF	Limited	Genetic Variation	[70]
NT5C3A	OT67KZJA	Limited	Biomarker	[343]
ORMDL3	OTAB7MZF	Limited	Genetic Variation	[344]
OTUD3	OTHUWQHP	Limited	Genetic Variation	[345]
PDZK1IP1	OTWA6M5K	Limited	Altered Expression	[337]
PKIG	OTOIWE5G	Limited	Genetic Variation	[70]
PLCG2	OTGVC9MY	Limited	Genetic Variation	[80]
PMP22	OTXWYWCZ	Limited	Altered Expression	[100]
PPP2R3C	OT7E6V9B	Limited	Genetic Variation	[70]
PUS10	OTFFJWZX	Limited	Genetic Variation	[80]
RAVER1	OTMHBTLE	Limited	Genetic Variation	[70]
RDX	OTNSYUN6	Limited	Genetic Variation	[70]
RGS14	OTYN79AG	Limited	Genetic Variation	[80]
RMI2	OTA0HP4S	Limited	Genetic Variation	[70]
RTEL1	OTI3PJCT	Limited	Genetic Variation	[71]
SBNO2	OT1C6J3K	Limited	Genetic Variation	[70]
SCYL1	OTQ0IN7P	Limited	Biomarker	[98]
SETD1A	OTVVWRIC	Limited	Genetic Variation	[70]
SKAP2	OTSF44KP	Limited	Genetic Variation	[70]
SP140	OTQZHFMT	Limited	Genetic Variation	[70]
STK11	OT1YZSP3	Limited	Genetic Variation	[70]
TAC1	OTM842YW	Limited	Biomarker	[346]
TFF3	OTJJDRTU	Limited	Altered Expression	[347]
THADA	OTYZQX0F	Limited	Genetic Variation	[70]
TMEM258	OTXSDU14	Limited	Genetic Variation	[70]
TNIP1	OTRAOTEW	Limited	Genetic Variation	[70]
TNXB	OTVBWAV5	Limited	Genetic Variation	[348]
TOM1	OT30QA56	Limited	Genetic Variation	[80]
TRIM15	OTNYAKP6	Limited	Genetic Variation	[196]
TSPAN14	OT29167O	Limited	Genetic Variation	[70]
ARHGDIA	OTEXWJDO	Disputed	Altered Expression	[349]
MICA	OTPEIEAR	Disputed	Biomarker	[350]
MUC12	OTYDC13T	Disputed	Biomarker	[351]
MUC13	OTWKS9MF	Disputed	Genetic Variation	[351]
PROSER1	OTV1Y4ON	Disputed	Genetic Variation	[352]
ACTR1A	OT1QAU16	moderate	Genetic Variation	[123]
ADGRL2	OTCXD2YR	moderate	Genetic Variation	[124]
ANKRD30A	OTJXYAE5	moderate	Genetic Variation	[124]
ATG16L1	OTEOYC5D	moderate	Genetic Variation	[353]
ATXN2L	OTP5M3R9	moderate	Genetic Variation	[124]
CCNY	OTK1KG5W	moderate	Genetic Variation	[71]
CELSR3	OT8P6QNJ	moderate	Genetic Variation	[123]
CRB1	OTXYUNG0	moderate	Genetic Variation	[124]
CYTH1	OTYH9NRJ	moderate	Genetic Variation	[123]
DEFA6	OTDJADMQ	moderate	Biomarker	[354]
DMBT1	OTVNU9D9	moderate	Altered Expression	[355]
DPH5	OT9UKOPV	moderate	Genetic Variation	[123]
DUSP16	OTK7S078	moderate	Genetic Variation	[123]
FNBP1	OTSJ5KKA	moderate	Genetic Variation	[124]
GP2	OTB6TMGY	moderate	Altered Expression	[356]
HORMAD2	OTL2ENWI	moderate	Genetic Variation	[123]
IKZF1	OTCW1FKL	moderate	Biomarker	[214]
IL17REL	OT0PG9GU	moderate	Genetic Variation	[344]
INS-IGF2	OTZR74BO	moderate	Genetic Variation	[124]
INTS11	OTOFT19G	moderate	Genetic Variation	[123]
LITAF	OTT5JX1F	moderate	Genetic Variation	[123]
LSP1	OTSPSIFO	moderate	Biomarker	[71]
LURAP1L	OTSJ29M5	moderate	Genetic Variation	[124]
MFSD13A	OTP306N2	moderate	Genetic Variation	[123]
NCAPD3	OTOZY2UL	moderate	Altered Expression	[133]
NKD1	OTY3MO97	moderate	Genetic Variation	[124]
PI3	OT47MTC3	moderate	Altered Expression	[357]
PLCL1	OTJL2C79	moderate	Genetic Variation	[123]
PNKD	OT6G9UXN	moderate	Genetic Variation	[123]
PROCR	OTRHED17	moderate	Genetic Variation	[123]
RTF1	OT6ZU71Q	moderate	Genetic Variation	[123]
SEMA6D	OTU0UAZS	moderate	Genetic Variation	[121]
SFMBT1	OTKMZIBW	moderate	Genetic Variation	[123]
SUOX	OTEJQ9FC	moderate	Genetic Variation	[124]
TET2	OTKKT03T	moderate	Genetic Variation	[123]
TMBIM1	OTE47B57	moderate	Genetic Variation	[123]
ACAT2	OTZ092ZJ	Strong	Altered Expression	[358]
ACSBG1	OTM040MW	Strong	Biomarker	[359]
ACTR3	OT05LJSH	Strong	Biomarker	[360]
ADCY3	OTGOQM6B	Strong	Genetic Variation	[104]
AFM	OTPOR8IO	Strong	Biomarker	[361]
AFTPH	OTDUYPRS	Strong	Altered Expression	[362]
AGA	OTNWT1WB	Strong	Biomarker	[363]
AGFG1	OTI8ZKC4	Strong	Biomarker	[364]
ALDOB	OT7FR69A	Strong	Altered Expression	[365]
AMY1A	OT6G4B8O	Strong	Altered Expression	[366]
ANKS1B	OT26DGM9	Strong	Biomarker	[367]
ANP32E	OTTWELUQ	Strong	Biomarker	[368]
APBA1	OTUH9JPD	Strong	Biomarker	[313]
APOBEC3A	OTYO6F5P	Strong	Altered Expression	[360]
AQP8	OT99JKME	Strong	Altered Expression	[369]
ARHGEF2	OTBQTFRT	Strong	Biomarker	[87]
ARHGEF28	OT3F32IU	Strong	Altered Expression	[354]
ARHGEF6	OTN1ABGL	Strong	Biomarker	[370]
ARMH1	OTTJC0D6	Strong	Biomarker	[87]
ASPRV1	OT8WVIBW	Strong	Biomarker	[371]
ATAD1	OTJ02XFL	Strong	Genetic Variation	[372]
ATG9A	OTAZWZH7	Strong	Biomarker	[373]
ATOH1	OTBZYG2R	Strong	Altered Expression	[374]
AZIN2	OT8OB7CG	Strong	Biomarker	[375]
BACH2	OT17GS18	Strong	Biomarker	[376]
BAHD1	OT9YGK94	Strong	Biomarker	[377]
BCKDHA	OT0LHOZB	Strong	Biomarker	[378]
BCL2L12	OTS6IFZY	Strong	Altered Expression	[183]
BCL3	OT1M5B95	Strong	Biomarker	[88]
BEST2	OT48WOL1	Strong	Altered Expression	[379]
BIN1	OTK8O0X8	Strong	Biomarker	[380]
BRINP3	OT4VFHWN	Strong	Altered Expression	[381]
BRWD1	OTOSRVDC	Strong	Biomarker	[382]
BSN	OTZ72VIB	Strong	Genetic Variation	[70]
BTNL2	OTTTEMZA	Strong	Genetic Variation	[344]
BVES	OT4GT1WC	Strong	Altered Expression	[383]
C4A	OTXMOYXU	Strong	Biomarker	[384]
C4BPB	OTJ70B0K	Strong	Biomarker	[385]
CALHM6	OTLX9B4Y	Strong	Genetic Variation	[386]
CAMK4	OT47RDGV	Strong	Altered Expression	[387]
CARD8	OTXXZYWU	Strong	Genetic Variation	[388]
CASZ1	OTWJ2OR8	Strong	Biomarker	[311]
CAVIN3	OTOLBK79	Strong	Altered Expression	[389]
CBFA2T3	OTOJ10S1	Strong	Biomarker	[390]
CCDC88B	OTEDUI2J	Strong	Altered Expression	[391]
CCL24	OT9LGHV0	Strong	Biomarker	[300]
CCL25	OTLWJ8CJ	Strong	Altered Expression	[392]
CCL26	OT2B7HR9	Strong	Biomarker	[393]
CCL4L2	OTDBSXOU	Strong	Altered Expression	[150]
CCL8	OTCTWYN8	Strong	Biomarker	[394]
CCNDBP1	OTBWG1M0	Strong	Biomarker	[395]
CD207	OTI9RUDN	Strong	Biomarker	[159]
CDAN1	OTCVZRG6	Strong	Biomarker	[396]
CDKAL1	OTA0SGNE	Strong	Genetic Variation	[70]
CDKN2D	OT2TTZPZ	Strong	Biomarker	[397]
CDX2	OTCG4TSY	Strong	Altered Expression	[398]
CGN	OTBCQ8AQ	Strong	Altered Expression	[399]
CHGA	OTXYX5JH	Strong	Biomarker	[400]
CHMP2B	OTZA7RJB	Strong	Altered Expression	[266]
CHMP5	OTQWZL6R	Strong	Altered Expression	[401]
CHRNA3	OTCZQY1U	Strong	Genetic Variation	[402]
CHST2	OTV11IZF	Strong	Biomarker	[403]
CISH	OT8T5NYL	Strong	Altered Expression	[404]
CITED2	OT812TV7	Strong	Altered Expression	[405]
CLEC7A	OTRTBH27	Strong	Genetic Variation	[406]
COL6A1	OTYKSCOB	Strong	Biomarker	[407]
COMMD1	OT7WUD5R	Strong	Genetic Variation	[408]
CORIN	OT4SK7DK	Strong	Biomarker	[148]
COX7A2L	OTY21FKV	Strong	Biomarker	[367]
CRNKL1	OTWBQNGU	Strong	Biomarker	[148]
CRX	OTH435SV	Strong	Genetic Variation	[262]
CRYGD	OTW29JC4	Strong	Altered Expression	[409]
CTBS	OT135K92	Strong	Biomarker	[253]
CUZD1	OTDQJVZ8	Strong	Biomarker	[410]
CXCL14	OTM189TA	Strong	Biomarker	[411]
CXCL5	OTZOUPCA	Strong	Biomarker	[412]
CXCL6	OTFTCQ4O	Strong	Biomarker	[413]
CYGB	OTX153DQ	Strong	Altered Expression	[414]
CYTB	OTAHB98A	Strong	Biomarker	[415]
D2HGDH	OTLHXW69	Strong	Altered Expression	[416]
DAP	OT5YLL7E	Strong	Genetic Variation	[70]
DBNL	OTT2OQOV	Strong	Genetic Variation	[141]
DCAF1	OT3ZDVOE	Strong	Biomarker	[364]
DCC	OT2C1SHW	Strong	Genetic Variation	[417]
DEFA5	OT95CBQ9	Strong	Biomarker	[418]
DEFB1	OT5SV0E4	Strong	Genetic Variation	[419]
DEFB103B	OT8RWY64	Strong	Biomarker	[420]
DEFB104A	OTLQZR6K	Strong	Altered Expression	[421]
DERL2	OTI3TUUZ	Strong	Biomarker	[118]
DMRT1	OT5PU9U1	Strong	Altered Expression	[266]
DNAJB5	OT7WDJ5C	Strong	Altered Expression	[177]
DOCK11	OTFSTN6A	Strong	Biomarker	[422]
DSG2	OTJPB2TO	Strong	Biomarker	[423]
DUOX2	OTU14HCN	Strong	Altered Expression	[424]
DUOXA2	OT7AZBZJ	Strong	Biomarker	[425]
EARS2	OTNCJKY7	Strong	Biomarker	[426]
EBNA1BP2	OTBRVMZH	Strong	Biomarker	[87]
EFNA5	OTOH4DRR	Strong	Biomarker	[427]
ELAVL2	OT6EJ8MQ	Strong	Genetic Variation	[428]
ELF3	OTUTLEQO	Strong	Biomarker	[147]
FAM107A	OTBG61YZ	Strong	Biomarker	[429]
FAM217B	OTDB4M8G	Strong	Posttranslational Modification	[430]
FCGR3B	OTSLSPZG	Strong	Genetic Variation	[431]
FCRL3	OTIFXFWL	Strong	Genetic Variation	[432]
FERMT1	OT626PBA	Strong	Biomarker	[433]
FLNB	OTPCOYL6	Strong	Genetic Variation	[434]
FUT2	OTLXM6WI	Strong	Genetic Variation	[435]
FZD1	OTZATHVS	Strong	Altered Expression	[436]
FZD3	OTIWDN78	Strong	Altered Expression	[436]
FZD5	OTXFFY56	Strong	Altered Expression	[436]
GADL1	OTJM4A0R	Strong	Biomarker	[375]
GAL3ST1	OTSFFZRD	Strong	Biomarker	[311]
GAS7	OT0M5TNY	Strong	Genetic Variation	[437]
GDE1	OTU6FSBF	Strong	Biomarker	[438]
GDF11	OTOSNMND	Strong	Biomarker	[439]
GNB4	OTC1GPHA	Strong	Biomarker	[440]
GNG11	OTHIXBGW	Strong	Biomarker	[440]
GORASP1	OTQS91S7	Strong	Biomarker	[136]
GPR15	OTK8674M	Strong	Altered Expression	[441]
GPR65	OTCF5O4G	Strong	Biomarker	[442]
GPX2	OTXI2NTI	Strong	Biomarker	[443]
GSDMB	OTWA7P10	Strong	Genetic Variation	[444]
GUCA2A	OTUSF75G	Strong	Altered Expression	[445]
GUCA2B	OTZERX04	Strong	Altered Expression	[445]
GZMA	OT43R33L	Strong	Biomarker	[446]
GZMM	OTEC5CWT	Strong	Biomarker	[447]
H1-0	OTRLJK4Z	Strong	Biomarker	[448]
H2AX	OT18UX57	Strong	Altered Expression	[449]
HAT1	OT307KEN	Strong	Altered Expression	[134]
HERC2	OTNQYKOB	Strong	Genetic Variation	[450]
HLA-DRA	OT7KZMP2	Strong	Genetic Variation	[451]
HLA-DRB3	OT5PM9N7	Strong	Biomarker	[452]
HNF4G	OTTSIHJP	Strong	Altered Expression	[453]
HSF2	OTXNJIJ9	Strong	Altered Expression	[454]
HSPA14	OTZCA5LK	Strong	Biomarker	[455]
ICAM2	OT3E070F	Strong	Biomarker	[456]
IFITM1	OTECO1G8	Strong	Genetic Variation	[457]
IFITM3	OT2QP8D3	Strong	Altered Expression	[458]
IFNGR1	OTCTQBWW	Strong	Genetic Variation	[207]
IL10RA	OTOX3D1D	Strong	Biomarker	[459]
IL17B	OTS86H50	Strong	Genetic Variation	[218]
IL17C	OTKXIVNQ	Strong	Biomarker	[411]
IL17RB	OT0KDNSF	Strong	Biomarker	[460]
IL17RC	OTEFOBSS	Strong	Biomarker	[460]
IL17RD	OTKD9XST	Strong	Biomarker	[461]
IL18R1	OT83XMPQ	Strong	Genetic Variation	[70]
IL26	OT2WYCW4	Strong	Altered Expression	[219]
IL34	OTZ15VVK	Strong	Altered Expression	[462]
IL6R	OTCQL07Z	Strong	Genetic Variation	[463]
IMPACT	OTQ923OB	Strong	Biomarker	[464]
INSRR	OT3F75WA	Strong	Biomarker	[465]
IRAK2	OT6Y1QZN	Strong	Altered Expression	[466]
IRF5	OT8SIIAP	Strong	Genetic Variation	[467]
ITPA	OTQ47WVR	Strong	Biomarker	[468]
KIAA1614	OTCG3B86	Strong	Posttranslational Modification	[430]
KIF21B	OTFXFIU3	Strong	Biomarker	[469]
KIR2DS3	OT3PSLDL	Strong	Genetic Variation	[228]
KIR2DS4	OT00N6UJ	Strong	Genetic Variation	[228]
KLF2	OTIP1UFX	Strong	Biomarker	[470]
KRT1	OTIOJWA4	Strong	Altered Expression	[471]
KYAT3	OTO4U2QK	Strong	Altered Expression	[134]
LACC1	OT4SBHI8	Strong	Genetic Variation	[472]
LAMB1	OT6J9LJR	Strong	Biomarker	[473]
LARS1	OT4557NF	Strong	Biomarker	[474]
LATS1	OTOOCG4R	Strong	Altered Expression	[475]
LDAH	OTXRU9XQ	Strong	Biomarker	[200]
LGALS14	OTOR23GX	Strong	Altered Expression	[165]
LRG1	OTLD0KWA	Strong	Altered Expression	[476]
LSAMP	OTYXVQX2	Strong	Biomarker	[104]
LXN	OTZQ2M6Y	Strong	Altered Expression	[477]
LY86	OTTZB64A	Strong	Altered Expression	[478]
LYRM4	OTK6JCKL	Strong	Genetic Variation	[479]
MACF1	OTVIHD77	Strong	Altered Expression	[480]
MAD2L1	OTXNGZCG	Strong	Altered Expression	[481]
MAF	OT1GR3IZ	Strong	Genetic Variation	[482]
MAP6	OTPUI00F	Strong	Biomarker	[483]
MAPRE1	OTCVQD60	Strong	Biomarker	[367]
MAPRE2	OTAE3MX4	Strong	Biomarker	[367]
MARCHF1	OTI2EYO6	Strong	Biomarker	[484]
MARCHF3	OT89V4N5	Strong	Genetic Variation	[485]
MARCO	OT0NW2Q0	Strong	Biomarker	[187]
MARVELD2	OTKB96L5	Strong	Altered Expression	[486]
MDFIC	OTSRYBWZ	Strong	Biomarker	[487]
MED25	OTDBY87B	Strong	Biomarker	[427]
MEP1A	OTY2Z48T	Strong	Altered Expression	[488]
MEPE	OTXJRUW0	Strong	Biomarker	[489]
MFSD2A	OTVG1VG0	Strong	Biomarker	[490]
MGAT5	OTU4DD4G	Strong	Biomarker	[491]
MIP	OTEBLU3E	Strong	Genetic Variation	[492]
MKS1	OT83W5PB	Strong	Altered Expression	[326]
MLC1	OTCNZLSP	Strong	Genetic Variation	[493]
MLKL	OTDSLC81	Strong	Altered Expression	[494]
MLN	OTBZ5SE5	Strong	Biomarker	[495]
MMP28	OTHQZXM1	Strong	Altered Expression	[496]
MOK	OTQK7M9V	Strong	Genetic Variation	[497]
MPG	OTAHW80B	Strong	Biomarker	[498]
MPIG6B	OTVNKQWA	Strong	Genetic Variation	[214]
MPRIP	OT5FV5NS	Strong	Altered Expression	[494]
MR1	OTZU3XX7	Strong	Genetic Variation	[499]
MSMP	OT20VCWP	Strong	Biomarker	[500]
MTFMT	OT1OIVJL	Strong	Biomarker	[501]
MUC20	OTYYE1GK	Strong	Biomarker	[502]
MUC3A	OTI4XUDY	Strong	Genetic Variation	[245]
MUC5B	OTPW6K5C	Strong	Altered Expression	[503]
MUC6	OTPVL723	Strong	Biomarker	[503]
MXI1	OTUQ9E0D	Strong	Altered Expression	[481]
MYDGF	OT9HRPL6	Strong	Genetic Variation	[81]
MYO9B	OTQ94R5K	Strong	Genetic Variation	[504]
MYOD1	OTV2S79X	Strong	Biomarker	[505]
NCKIPSD	OT24UORN	Strong	Biomarker	[395]
ND4	OT4RQVAA	Strong	Genetic Variation	[506]
NEURL1	OT2C4P70	Strong	Biomarker	[507]
NFATC1	OT4TMERS	Strong	Genetic Variation	[70]
NFKBIL1	OTYFTPS0	Strong	Biomarker	[508]
NKX2-3	OTF4IL5J	Strong	Genetic Variation	[508]
NLRP12	OTGR132Z	Strong	Biomarker	[509]
NLRP7	OTE9BI32	Strong	Genetic Variation	[510]
NOX1	OTZPJQCC	Strong	Genetic Variation	[511]
NR1D2	OT9CVF41	Strong	Altered Expression	[512]
NSG1	OTRIMA50	Strong	Altered Expression	[513]
NUCKS1	OTL4VJC5	Strong	Biomarker	[449]
NUDT1	OTZSES3W	Strong	Altered Expression	[514]
NXF1	OTEFHXG6	Strong	Genetic Variation	[434]
NXPE4	OTWDLYH5	Strong	Altered Expression	[414]
OCLN	OTSUTVWL	Strong	Altered Expression	[515]
OPN1LW	OTFNUZ7O	Strong	Biomarker	[516]
OR10A4	OTYYB8SY	Strong	Biomarker	[517]
ORM2	OTRJGZP8	Strong	Altered Expression	[518]
PADI2	OTT40K94	Strong	Altered Expression	[519]
PAEP	OTQA0NV4	Strong	Biomarker	[498]
PAG1	OTFOJUIQ	Strong	Biomarker	[516]
PANX1	OTXPEDOK	Strong	Altered Expression	[520]
PANX2	OTAQ2S8R	Strong	Altered Expression	[521]
PARD3	OTH5BPLO	Strong	Genetic Variation	[522]
PCBP4	OTDLL4NB	Strong	Biomarker	[516]
PER3	OTVKYVJA	Strong	Altered Expression	[512]
PGLYRP1	OTBTPR2T	Strong	Genetic Variation	[523]
PIK3R3	OTXGJ8N1	Strong	Biomarker	[440]
PLA2G6	OT5FL0WU	Strong	Altered Expression	[103]
PLB1	OTZ6TTYV	Strong	Genetic Variation	[95]
PLBD2	OTD8YYTL	Strong	Biomarker	[524]
PLIN2	OTRXJ9UN	Strong	Altered Expression	[525]
PNN	OT0HXICH	Strong	Biomarker	[507]
POP5	OTCZTDJC	Strong	Biomarker	[526]
POP7	OTKC7SG5	Strong	Biomarker	[526]
PRDM1	OTQLSVBS	Strong	Genetic Variation	[70]
PRDX3	OTLB2WEU	Strong	Altered Expression	[527]
PRRC2A	OTBX6FM5	Strong	Genetic Variation	[77]
PSD	OTUZIXUZ	Strong	Posttranslational Modification	[528]
PSMA7	OTPHI6ST	Strong	Altered Expression	[529]
PSMD7	OT7PZZ4K	Strong	Biomarker	[87]
PSMG1	OTZ5I6UM	Strong	Genetic Variation	[530]
PSTPIP1	OT4PGEAB	Strong	Genetic Variation	[531]
PTPN4	OT6SXU5Y	Strong	Biomarker	[532]
RABEPK	OTCZSREH	Strong	Biomarker	[87]
RAG2	OTG9UYTW	Strong	Biomarker	[533]
RBM47	OT6W67VM	Strong	Altered Expression	[534]
RBMXL1	OTMGCWWB	Strong	Altered Expression	[134]
RELA	OTUJP9CN	Strong	Biomarker	[136]
RIBC2	OTDB4FM2	Strong	Posttranslational Modification	[430]
RIPK3	OTL1D484	Strong	Altered Expression	[494]
RMC1	OT7K8MTJ	Strong	Biomarker	[535]
RNASE2	OT8Z4FNE	Strong	Biomarker	[536]
RNF128	OTJO86CJ	Strong	Altered Expression	[537]
RNF186	OTXNX8VL	Strong	Genetic Variation	[538]
RPAIN	OTBMXAYK	Strong	Biomarker	[364]
RPLP2	OT2YBK3W	Strong	Biomarker	[526]
RPTOR	OT4TQZ9F	Strong	Biomarker	[539]
RRM2B	OTE8GBUR	Strong	Biomarker	[540]
RTL1	OTOT33IM	Strong	Biomarker	[541]
SCNN1B	OT61QQTL	Strong	Altered Expression	[542]
SCNN1G	OTSJYQVQ	Strong	Altered Expression	[542]
SEC14L2	OTJST64D	Strong	Genetic Variation	[434]
SELENOS	OTUEWIU9	Strong	Genetic Variation	[543]
SEMA3E	OTD4S36H	Strong	Altered Expression	[544]
SERPINE2	OTYF5340	Strong	Biomarker	[545]
SETMAR	OTE2MIMZ	Strong	Biomarker	[541]
SFRP2	OT8GZ0CA	Strong	Biomarker	[546]
SGPP2	OTIDIJCR	Strong	Biomarker	[547]
SGSM3	OTIB1P8A	Strong	Biomarker	[175]
SLC12A9	OTR7VRAK	Strong	Biomarker	[548]
SLPI	OTUNFUU8	Strong	Biomarker	[549]
SLURP1	OT89YD2E	Strong	Genetic Variation	[550]
SNX20	OTNL4B1S	Strong	Biomarker	[104]
ST6GALNAC1	OT3JQD99	Strong	Altered Expression	[551]
STX2	OTO2IDDR	Strong	Altered Expression	[552]
SYT1	OTVTPOI6	Strong	Biomarker	[136]
TAGAP	OTHJNNO2	Strong	Altered Expression	[376]
TAP2	OTWSYFI7	Strong	Altered Expression	[553]
TAX1BP1	OTGJMGJ9	Strong	Altered Expression	[224]
TCEAL1	OTAPG2L5	Strong	Biomarker	[554]
TCERG1L	OTSBSCLF	Strong	Posttranslational Modification	[555]
TCF4	OTB9ASTK	Strong	Genetic Variation	[556]
TCF7	OT1ID822	Strong	Biomarker	[153]
TCN2	OT41D0L3	Strong	Genetic Variation	[557]
TFF2	OTRXB19X	Strong	Biomarker	[558]
TIA1	OTGPN3P8	Strong	Altered Expression	[559]
TIAL1	OTV2KFZH	Strong	Genetic Variation	[559]
TIGAR	OTR7NMRJ	Strong	Biomarker	[560]
TJP1	OTBDCUPK	Strong	Biomarker	[561]
TNFAIP6	OT1SLUZH	Strong	Altered Expression	[562]
TNFRSF10C	OTVHOL9B	Strong	Biomarker	[563]
TNFRSF6B	OTKAN9G7	Strong	Biomarker	[104]
TOLLIP	OTYEO4NR	Strong	Biomarker	[88]
TPD52L1	OTSA6U0I	Strong	Altered Expression	[564]
TRAF3	OT5TQBGV	Strong	Altered Expression	[565]
TRAF3IP2	OTLLZERL	Strong	Genetic Variation	[566]
TRAF5	OTSBTLO0	Strong	Altered Expression	[565]
TRIM58	OT7OIIRH	Strong	Altered Expression	[567]
ARPC2	OTSOKOMY	Definitive	Genetic Variation	[437]
CLEC10A	OTD8HQT6	Definitive	Biomarker	[303]
CLEC4A	OTNLPK2C	Definitive	Biomarker	[303]
ELMO1	OTY2ORXK	Definitive	Genetic Variation	[206]
FBLN5	OTLVNZ8U	Definitive	Biomarker	[568]
MAGT1	OTQSAV5C	Definitive	Altered Expression	[139]
RABGEF1	OTWC3Z3R	Definitive	Biomarker	[306]
RAVER2	OT0MDL7K	Definitive	Genetic Variation	[569]
REEP6	OTY4FPO8	Definitive	Genetic Variation	[570]
TERF2IP	OT3M5P3G	Definitive	Biomarker	[306]
TRAIP	OTMPT9Y2	Definitive	Genetic Variation	[571]

References

• [1] First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol. 2020 Sep;18(10):2179-2191.e6.
• [2] Aminosalicylic acid FDA Label
• [3] Budesonide FDA Label
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Cortisone acetate FDA Label
• [6] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216956
• [7] Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):161-170.
• [8] Hydrocortisone FDA Label
• [9] Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76.
• [10] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4655).
• [12] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761279
• [13] Naltrexone FDA Label
• [14] ClinicalTrials.gov (NCT00004288) Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis. U.S. National Institutes of Health.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Prednisolone FDA Label
• [17] Sulfadiazine FDA Label
• [18] Sulfasalazine FDA Label
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8001).
• [20] ClinicalTrials.gov (NCT01400945) Efficacy Study of AGSPT201 Tablet to Treat Gastroesophageal Reflux Disease. U.S. National Institutes of Health.
• [21] Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
• [22] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [23] ClinicalTrials.gov (NCT04277546) A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE). U.S.National Institutes of Health.
• [24] ClinicalTrials.gov (NCT01493960) The Efficacy and Safety of Kappaproct in Chronic Active Treatment Refractory Ulcerative Colitis Patients. U.S. National Institutes of Health.
• [25] ClinicalTrials.gov (NCT02280629) Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2). U.S. National Institutes of Health.
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026082)
• [27] ClinicalTrials.gov (NCT03259334) Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis (FIGARO UC 301). U.S. National Institutes of Health.
• [28] ClinicalTrials.gov (NCT05181137) A Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. U.S.National Institutes of Health.
• [29] Clinical pipeline report, company report or official report of Adiso Therapeutics
• [30] Gingival crevicular fluid alkaline phosphatase levels in postmenopausal women: effects of phase I periodontal treatment. J Periodontol. 2006 Jan;77(1):67-72.
• [31] ClinicalTrials.gov (NCT04857112) A Phase 2, Randomized, Double-Blinded, Placebo Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects With Mild to Moderate Ulcerative Colitis (UC). U.S.National Institutes of Health.
• [32] ClinicalTrials.gov (NCT05372939) A Randomized, Placebo-controlled, Double-blind, Parallel-group, Exploratory, Phase 2 Study of the Efficacy and Safety of Oral AMT-101 in Combination With Adalimumab in Subjects With Moderate to Severe Ulcerative Colitis. U.S.National Institutes of Health.
• [33] ClinicalTrials.gov (NCT00425061) Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma. U.S. National Institutes of Health.
• [34] ClinicalTrials.gov (NCT01466374) Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease. U.S. National Institutes of Health.
• [35] ClinicalTrials.gov (NCT01612039) Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis. U.S. National Institutes of Health.
• [36] ClinicalTrials.gov (NCT04700449) A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC). U.S.National Institutes of Health.
• [37] ClinicalTrials.gov (NCT05588843) A Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Assess the Efficacy and Safety of SAR443122 in Adult Patients With Moderate to Severe Ulcerative Colitis. U.S.National Institutes of Health.
• [38] ClinicalTrials.gov (NCT04987307) A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. U.S.National Institutes of Health.
• [39] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [40] ClinicalTrials.gov (NCT05242484) A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis. U.S.National Institutes of Health.
• [41] ClinicalTrials.gov (NCT04074590) A Randomized, Multi-center, Subject and Investigator-blinded, Placebo-controlled, Parallel-group Study to Assess the Efficacy Safety and Tolerability of LYS006 in Patients With Mild to Moderate Ulcerative Colitis. U.S.National Institutes of Health.
• [42] ClinicalTrials.gov (NCT05291689) A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1). U.S.National Institutes of Health.
• [43] ClinicalTrials.gov (NCT05785715) A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study With Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants w/ Moderate to Severe Ulcerative Colitis. U.S.National Institutes of Health.
• [44] ClinicalTrials.gov (NCT05057273) A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease. U.S.National Institutes of Health.
• [45] ClinicalTrials.gov (NCT05466890) Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, PK and Biomarkers With Oral Colon Delivery PL8177 in Adult Subjects With Active Ulcerative Colitis. U.S.National Institutes of Health.
• [46] ClinicalTrials.gov (NCT04504383) A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Oral PN-943 in Subjects With Moderate to Severe Active Ulcerative Colitis. U.S.National Institutes of Health.
• [47] ClinicalTrials.gov (NCT04996797) A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis. U.S.National Institutes of Health.
• [48] ClinicalTrials.gov (NCT00243074) S0509: AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery. U.S. National Institutes of Health.
• [49] Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
• [50] ClinicalTrials.gov (NCT01983306) Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC). U.S. National Institutes of Health.
• [51] ClinicalTrials.gov (NCT05770609) A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Dose-finding Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH3127 Tablets in the Treatment of Mild to Moderate Ulcerative Colitis. U.S.National Institutes of Health.
• [52] ClinicalTrials.gov (NCT05156125) A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects With Moderately to Severely Active Ulcerative Colitis. U.S.National Institutes of Health.
• [53] ClinicalTrials.gov (NCT05084261) A Multicenter, Randomized, Placebo-Controlled, Multiple-Ascending-Dose Investigation of the Oral Anti-Inflammatory Agent BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC). U.S.National Institutes of Health.
• [54] ClinicalTrials.gov (NCT04924114) A Phase 1b, Randomized, Adaptive, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of PT101 in Subjects With Active Ulcerative Colitis. U.S.National Institutes of Health.
• [55] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030237)
• [56] Clinical pipeline report, company report or official report of Gastroenterology.
• [57] Clinical pipeline report, company report or official report of Azora Therapeutics
• [58] Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55.
• [59] Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97.
• [60] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000604)
• [61] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006120)
• [62] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000641)
• [63] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 901).
• [64] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019860)
• [65] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [66] Asphelia to Present at C21 BioVentures Conference in Napa, CA. 10th Annual C21 BioVentures. May 15, 2008.
• [67] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343).
• [68] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849).
• [69] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
• [70] Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci.Nat Genet. 2016 May;48(5):510-8. doi: 10.1038/ng.3528. Epub 2016 Mar 14.
• [71] Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.Nat Genet. 2011 Mar;43(3):246-52. doi: 10.1038/ng.764. Epub 2011 Feb 6.
• [72] Disorder-to-helix conformational conversion of the human immunomodulatory peptide LL-37 induced by antiinflammatory drugs, food dyes and some metabolites.Int J Biol Macromol. 2019 May 15;129:50-60. doi: 10.1016/j.ijbiomac.2019.01.209. Epub 2019 Feb 1.
• [73] IL-12 and Mucosal CD14+ Monocyte-Like Cells Induce IL-8 in Colonic Memory CD4+ T Cells of Patients With Ulcerative Colitis but not Crohn's Disease.J Crohns Colitis. 2020 Jan 1;14(1):79-95. doi: 10.1093/ecco-jcc/jjz115.
• [74] Association between functional CD24 polymorphisms and susceptibility to autoimmune diseases: A meta-analysis.Cell Mol Biol (Noisy-le-grand). 2015 Dec 26;61(8):97-104.
• [75] CD80-CD28 signaling controls the progression of inflammatory colorectal carcinogenesis.Oncotarget. 2015 Aug 21;6(24):20058-69. doi: 10.18632/oncotarget.2780.
• [76] E6130, a Novel CX3C Chemokine Receptor 1 (CX3CR1) Modulator, Attenuates Mucosal Inflammation and Reduces CX3CR1(+) Leukocyte Trafficking in Mice with Colitis.Mol Pharmacol. 2017 Nov;92(5):502-509. doi: 10.1124/mol.117.108381. Epub 2017 Aug 25.
• [77] Genome-wide association scan in north Indians reveals three novel HLA-independent risk loci for ulcerative colitis.Gut. 2015 Apr;64(4):571-9. doi: 10.1136/gutjnl-2013-306625. Epub 2014 May 16.
• [78] Protective role of Interleukin 27 (IL-27) gene polymorphisms in patients with ulcerative colitis.Immunol Lett. 2016 Apr;172:79-83. doi: 10.1016/j.imlet.2016.02.010. Epub 2016 Feb 18.
• [79] A population- and family-based study of Canadian families reveals association of HLA DRB1*0103 with colonic involvement in inflammatory bowel disease.Inflamm Bowel Dis. 2003 Jan;9(1):1-9. doi: 10.1097/00054725-200301000-00001.
• [80] Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.Nat Genet. 2017 Feb;49(2):256-261. doi: 10.1038/ng.3760. Epub 2017 Jan 9.
• [81] Functional variant in the promoter region of IL-27 alters gene transcription and confers a risk for ulcerative colitis in northern Chinese Han.Hum Immunol. 2017 Mar;78(3):287-293. doi: 10.1016/j.humimm.2017.01.002. Epub 2017 Jan 6.
• [82] Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease.PLoS One. 2019 Apr 19;14(4):e0215033. doi: 10.1371/journal.pone.0215033. eCollection 2019.
• [83] Anti-interleukin-23 agents for the treatment of ulcerative colitis.Expert Opin Biol Ther. 2020 Apr;20(4):399-406. doi: 10.1080/14712598.2020.1697227. Epub 2019 Nov 27.
• [84] Interleukin-33 delays recovery of mucosal inflammation via downregulation of homeostatic ABCG5/8 in the colon.Lab Invest. 2020 Mar;100(3):491-502. doi: 10.1038/s41374-019-0329-3. Epub 2019 Oct 22.
• [85] Progress in active compounds effective on ulcerative colitis from Chinese medicines.Chin J Nat Med. 2019 Feb;17(2):81-102. doi: 10.1016/S1875-5364(19)30012-3.
• [86] IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease.J Clin Invest. 2019 Apr 2;129(5):1910-1925. doi: 10.1172/JCI121668. eCollection 2019 Apr 2.
• [87] Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.Expert Opin Investig Drugs. 2019 May;28(5):473-479. doi: 10.1080/13543784.2019.1597053. Epub 2019 Mar 26.
• [88] Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?.Clin Exp Immunol. 2016 Mar;183(3):358-68. doi: 10.1111/cei.12732. Epub 2015 Nov 26.
• [89] Extracellular vesicles derived from bone marrow mesenchymal stem cells attenuate dextran sodium sulfate-induced ulcerative colitis by promoting M2 macrophage polarization.Int Immunopharmacol. 2019 Jul;72:264-274. doi: 10.1016/j.intimp.2019.04.020. Epub 2019 Apr 17.
• [90] Decreased potassium channel IK1 and its regulator neurotrophin-3 (NT-3) in inflamed human bowel.Neuroreport. 2003 Feb 10;14(2):191-5. doi: 10.1097/00001756-200302100-00006.
• [91] Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease.Dig Dis Sci. 2003 Mar;48(3):615-23. doi: 10.1023/a:1022569623350.
• [92] Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases.J Clin Gastroenterol. 2018 Aug;52(7):e53-e62. doi: 10.1097/MCG.0000000000000837.
• [93] Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis.Gastroenterology. 1999 Oct;117(4):806-13. doi: 10.1016/s0016-5085(99)70338-0.
• [94] Gene expression signature and the prediction of ulcerative colitis-associated colorectal cancer by DNA microarray.Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):415-20. doi: 10.1158/1078-0432.CCR-06-0753.
• [95] Genetic Variations at rs3129891 and rs77005575 are Associated With Reduced Expression of Enteric -defensins in IBD Patients.J Clin Gastroenterol. 2020 Jul;54(6):e50-e55. doi: 10.1097/MCG.0000000000001146.
• [96] Matrix metalloproteinases cleave membrane-bound PD-L1 on CD90+ (myo-)fibroblasts in Crohn's disease and regulate Th1/Th17 cell responses.Int Immunol. 2020 Jan 9;32(1):57-68. doi: 10.1093/intimm/dxz060.
• [97] MiR-146a regulates the development of ulcerative colitis via mediating the TLR4/MyD88/NF-B signaling pathway.Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2151-2157. doi: 10.26355/eurrev_201903_17260.
• [98] Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis.J Clin Invest. 2006 Dec;116(12):3195-203. doi: 10.1172/JCI28804. Epub 2006 Nov 22.
• [99] Homology modeling and in silico prediction of Ulcerative colitis associated polymorphisms of NOD1.Mol Cell Probes. 2017 Oct;35:8-19. doi: 10.1016/j.mcp.2017.05.009. Epub 2017 Jun 1.
• [100] Suppression of miR-21 and miR-155 of macrophage by cinnamaldehyde ameliorates ulcerative colitis.Int Immunopharmacol. 2019 Feb;67:22-34. doi: 10.1016/j.intimp.2018.11.045. Epub 2018 Dec 6.
• [101] Pregnane X Receptor Polymorphisms and Risk of Inflammatory Bowel Disease: A Meta-Analysis.Immunol Invest. 2017 Aug;46(6):566-576. doi: 10.1080/08820139.2017.1322101. Epub 2017 Jul 25.
• [102] Lack of an association between polymorphisms of the T-cell receptor alpha-chain and ulcerative colitis.Gastroenterology. 1989 Nov;97(5):1115-20. doi: 10.1016/0016-5085(89)91680-6.
• [103] Expression of group XIIA phospholipase A2 in human digestive organs.APMIS. 2014 Dec;122(12):1171-7. doi: 10.1111/apm.12280. Epub 2014 May 26.
• [104] Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease.Gastroenterology. 2017 Jan;152(1):206-217.e2. doi: 10.1053/j.gastro.2016.09.032. Epub 2016 Sep 28.
• [105] Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.Nature. 2012 Nov 1;491(7422):119-24. doi: 10.1038/nature11582.
• [106] Polymorphism in ICAM-1, PECAM-1, E-selectin, and L-selectin genes in Tunisian patients with inflammatory bowel disease.Eur J Gastroenterol Hepatol. 2009 Feb;21(2):167-75. doi: 10.1097/MEG.0b013e32830e6fc8.
• [107] Colonic Epithelial Surfactant Protein D Expression Correlates with Inflammation in Clinical Colonic Inflammatory Bowel Disease.Inflamm Bowel Dis. 2019 Jul 17;25(8):1349-1356. doi: 10.1093/ibd/izz009.
• [108] Distinct differences in tachykinin gene expression in ulcerative colitis, Crohn's disease and diverticular disease: a role for hemokinin-1?.Neurogastroenterol Motil. 2011 May;23(5):475-83, e179-80. doi: 10.1111/j.1365-2982.2011.01685.x. Epub 2011 Feb 22.
• [109] Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine.Am J Pathol. 2000 Nov;157(5):1511-22. doi: 10.1016/S0002-9440(10)64789-X.
• [110] The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis.J Crohns Colitis. 2020 May 21;14(4):508-524. doi: 10.1093/ecco-jcc/jjz170.
• [111] MicroRNA-31 Targets Thymic Stromal Lymphopoietin in Mucosal Infiltrated CD4+ T Cells: A Role in Achieving Mucosal Healing in Ulcerative Colitis?.Inflamm Bowel Dis. 2018 Oct 12;24(11):2377-2385. doi: 10.1093/ibd/izy213.
• [112] Upregulation of intestinal mucosal mast cells expressing VPAC1 in close proximity to vasoactive intestinal polypeptide in inflammatory bowel disease and murine colitis.Neurogastroenterol Motil. 2019 Mar;31(3):e13503. doi: 10.1111/nmo.13503. Epub 2018 Nov 8.
• [113] Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease.Inflamm Bowel Dis. 2007 Apr;13(4):391-7. doi: 10.1002/ibd.20078.
• [114] CD209 in inflammatory bowel disease: a case-control study in the Spanish population.BMC Med Genet. 2007 Dec 10;8:75. doi: 10.1186/1471-2350-8-75.
• [115] Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease.Gastroenterology. 2008 Jul;135(1):173-84. doi: 10.1053/j.gastro.2008.04.002. Epub 2008 Apr 11.
• [116] Aberrant alteration of follicular T helper cells in ulcerative colitis patients and its correlations with interleukin-21 and B cell subsets.Medicine (Baltimore). 2019 Mar;98(10):e14757. doi: 10.1097/MD.0000000000014757.
• [117] Inflammatory Bowel Disease Types Differ in Markers of Inflammation, Gut Barrier and in Specific Anti-Bacterial Response.Cells. 2019 Jul 13;8(7):719. doi: 10.3390/cells8070719.
• [118] I219V polymorphism in hMLH1 gene in patients affected with ulcerative colitis.Genet Test Mol Biomarkers. 2009 Apr;13(2):193-7. doi: 10.1089/gtmb.2008.0088.
• [119] Differential expression of vasoactive intestinal peptide receptor 1 expression in inflammatory bowel disease.Int J Mol Med. 2007 Aug;20(2):161-7.
• [120] Role of 2-adrenoceptor--arrestin2-nuclear factor-B signal transduction pathway and intervention effects of oxymatrine in ulcerative colitis.Chin J Integr Med. 2012 Jul;18(7):514-21. doi: 10.1007/s11655-012-1146-3. Epub 2012 Jul 7.
• [121] Genetic architecture differences between pediatric and adult-onset inflammatory bowel diseases in the Polish population.Sci Rep. 2016 Dec 23;6:39831. doi: 10.1038/srep39831.
• [122] In-silico guided discovery of novel CCR9 antagonists.J Comput Aided Mol Des. 2018 Apr;32(4):573-582. doi: 10.1007/s10822-018-0113-2. Epub 2018 Mar 26.
• [123] Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.Nat Genet. 2015 Sep;47(9):979-986. doi: 10.1038/ng.3359. Epub 2015 Jul 20.
• [124] Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases.Nat Med. 2015 Sep;21(9):1018-27. doi: 10.1038/nm.3933. Epub 2015 Aug 24.
• [125] Herb-partitioned moxibustion alleviates colon injuries in ulcerative colitis rats.World J Gastroenterol. 2018 Aug 14;24(30):3384-3397. doi: 10.3748/wjg.v24.i30.3384.
• [126] Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves.J Physiol Pharmacol. 2009 Jun;60(2):41-7.
• [127] Altered microRNA Expression and Immunosuppressive Cytokine Production by Regulatory T Cells of Ulcerative Colitis Patients.Immunol Invest. 2016;45(1):63-74. doi: 10.3109/08820139.2015.1103749.
• [128] Therapeutic potential of iron chelators in diseases associated with iron mismanagement.J Pharm Pharmacol. 2006 May;58(5):575-84. doi: 10.1211/jpp.58.5.0001.
• [129] Genetic variations in matrix metalloproteinases may be associated with increased risk of ulcerative colitis.Hum Immunol. 2011 Nov;72(11):1117-27. doi: 10.1016/j.humimm.2011.08.011. Epub 2011 Aug 30.
• [130] Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort.PLoS One. 2014 Jun 27;9(6):e98815. doi: 10.1371/journal.pone.0098815. eCollection 2014.
• [131] Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease.J Gastroenterol Hepatol. 2018 Mar 7. doi: 10.1111/jgh.14140. Online ahead of print.
• [132] Expression of human REG family genes in inflammatory bowel disease and their molecular mechanism.Immunol Res. 2018 Dec;66(6):800-805. doi: 10.1007/s12026-019-9067-2.
• [133] Chromosome-associated protein D3 promotes bacterial clearance in human intestinal epithelial cells by repressing expression of amino acid transporters.Gastroenterology. 2015 Jun;148(7):1405-1416.e3. doi: 10.1053/j.gastro.2015.02.013. Epub 2015 Feb 18.
• [134] Increased expression of kynurenine aminotransferases mRNA in lymphocytes of patients with inflammatory bowel disease.Therap Adv Gastroenterol. 2019 Oct 19;12:1756284819881304. doi: 10.1177/1756284819881304. eCollection 2019.
• [135] microRNA-15 Activates NF-B Pathway via Down Regulating Expression of Adenosine A2 Receptor in Ulcerative Colitis.Cell Physiol Biochem. 2018;51(4):1932-1944. doi: 10.1159/000495718. Epub 2018 Dec 4.
• [136] Activation of adenosine A3 receptor inhibits inflammatory cytokine production in colonic mucosa of patients with ulcerative colitis by down-regulating the nuclear factor-kappa B signaling.J Dig Dis. 2020 Jan;21(1):38-45. doi: 10.1111/1751-2980.12831. Epub 2019 Dec 17.
• [137] Association of alpha 2A adrenergic receptor gene (ADRAlpha2A) polymorphism with irritable bowel syndrome, microscopic and ulcerative colitis.Clin Chim Acta. 2010 Jan;411(1-2):59-63. doi: 10.1016/j.cca.2009.10.003. Epub 2009 Oct 13.
• [138] Norisoboldine, a natural AhR agonist, promotes Treg differentiation and attenuates colitis via targeting glycolysis and subsequent NAD(+)/SIRT1/SUV39H1/H3K9me3 signaling pathway.Cell Death Dis. 2018 Feb 15;9(3):258. doi: 10.1038/s41419-018-0297-3.
• [139] Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease.World J Gastroenterol. 2012 Jul 7;18(25):3254-9. doi: 10.3748/wjg.v18.i25.3254.
• [140] Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis.Nat Rev Gastroenterol Hepatol. 2011 Jun 7;8(7):395-404. doi: 10.1038/nrgastro.2011.96.
• [141] Severity of ulcerative colitis is associated with a polymorphism at diamine oxidase gene but not at histamine N-methyltransferase gene.World J Gastroenterol. 2006 Jan 28;12(4):615-20. doi: 10.3748/wjg.v12.i4.615.
• [142] Relationship and significance between anti-beta2-glycoprotein I antibodies and platelet activation state in patients with ulcerative colitis.World J Gastroenterol. 2008 Feb 7;14(5):771-5. doi: 10.3748/wjg.14.771.
• [143] -Arrestin2 encourages inflammation-induced epithelial apoptosis through ER stress/PUMA in colitis.Mucosal Immunol. 2015 May;8(3):683-95. doi: 10.1038/mi.2014.104. Epub 2014 Nov 5.
• [144] Upregulation of cIAP2 in regenerating colonocytes in ulcerative colitis.Virchows Arch. 2007 Dec;451(6):1031-8. doi: 10.1007/s00428-007-0517-1. Epub 2007 Oct 31.
• [145] Carbonic anhydrase I reduction in colonic mucosa of patients with active ulcerative colitis.Dig Dis Sci. 1998 Sep;43(9):2086-92. doi: 10.1023/a:1018819600645.
• [146] Colonic Mucosal Transcriptomic Changes in Patients with Long-Duration Ulcerative Colitis Revealed Colitis-Associated Cancer Pathways.J Crohns Colitis. 2019 May 27;13(6):755-763. doi: 10.1093/ecco-jcc/jjz002.
• [147] Epithelial-specific ETS-1 (ESE1/ELF3) regulates apoptosis of intestinal epithelial cells in ulcerative colitis via accelerating NF-B activation.Immunol Res. 2015 Jun;62(2):198-212. doi: 10.1007/s12026-015-8651-3.
• [148] Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease.Aliment Pharmacol Ther. 2013 Mar;37(5):546-54. doi: 10.1111/apt.12218. Epub 2013 Jan 24.
• [149] Effect of secondary lymphoid tissue chemokine suppression on experimental ulcerative colitis in mice.Genet Mol Res. 2014 Apr 29;13(2):3337-45. doi: 10.4238/2014.April.29.12.
• [150] Inflammatory gene expression profiles in Crohn's disease and ulcerative colitis: a comparative analysis using a reverse transcriptase multiplex ligation-dependent probe amplification protocol.J Crohns Colitis. 2013 Sep;7(8):622-30. doi: 10.1016/j.crohns.2012.08.015. Epub 2012 Sep 24.
• [151] Impact of smoking cigarette on the mRNA expression of cytokines in mucosa of inflammatory bowel disease.Physiol Res. 2019 Nov 30;68(Suppl 2):S183-S192. doi: 10.33549/physiolres.934301.
• [152] Upregulated IL-17A secretion and CCR6 co-expression in Treg subsets are related to the imbalance of Treg/Th17 cells in active UC patients.Scand J Immunol. 2020 Jun;91(6):e12842. doi: 10.1111/sji.12842. Epub 2019 Nov 24.
• [153] Differential Pathogenic Th17 Profile in Mesenteric Lymph Nodes of Crohn's Disease and Ulcerative Colitis Patients.Front Immunol. 2019 May 28;10:1177. doi: 10.3389/fimmu.2019.01177. eCollection 2019.
• [154] CD1a-Expressing Monocytes as Mediators of Inflammation in Ulcerative Colitis.Inflamm Bowel Dis. 2018 May 18;24(6):1225-1236. doi: 10.1093/ibd/izy073.
• [155] Assessment of Fecal ASCA Measurement as a Biomarker of Crohn Disease in Pediatric Patients.J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):248-253. doi: 10.1097/MPG.0000000000001244.
• [156] CD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis.J Leukoc Biol. 2013 Nov;94(5):1061-70. doi: 10.1189/jlb.1212640. Epub 2013 Jul 31.
• [157] Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia.Int J Mol Sci. 2019 Jan 4;20(1):166. doi: 10.3390/ijms20010166.
• [158] Increased serum concentrations and surface expression on peripheral white blood cells of decay-accelerating factor (CD55) in patients with active ulcerative colitis.J Lab Clin Med. 2004 Mar;143(3):152-8. doi: 10.1016/j.lab.2003.11.004.
• [159] Altered human gut dendritic cell properties in ulcerative colitis are reversed by Lactobacillus plantarum extracellular encrypted peptide STp.Mol Nutr Food Res. 2014 May;58(5):1132-43. doi: 10.1002/mnfr.201300596. Epub 2013 Dec 18.
• [160] Genes involved in the regulation of intestinal permeability and their role in ulcerative colitis.J Dig Dis. 2015 Dec;16(12):713-22. doi: 10.1111/1751-2980.12296.
• [161] Cadherin-11 Is a Regulator of Intestinal Fibrosis.J Crohns Colitis. 2020 Mar 13;14(3):406-417. doi: 10.1093/ecco-jcc/jjz147.
• [162] Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells.Mol Ther. 2014 May;22(5):1018-28. doi: 10.1038/mt.2014.41. Epub 2014 Mar 6.
• [163] A cross-ethnic survey of CFB and SLC44A4, Indian ulcerative colitis GWAS hits, underscores their potential role in disease susceptibility.Eur J Hum Genet. 2016 Jan;25(1):111-122. doi: 10.1038/ejhg.2016.131. Epub 2016 Oct 19.
• [164] Oligonucleotides-A Novel Promising Therapeutic Option for IBD.Front Pharmacol. 2019 Apr 24;10:314. doi: 10.3389/fphar.2019.00314. eCollection 2019.
• [165] Chloride channel ClC-2 is a key factor in the development of DSS-induced murine colitis.Inflamm Bowel Dis. 2013 Dec;19(13):2867-77. doi: 10.1097/MIB.0b013e3182a82ae9.
• [166] Increased expression of the tight junction molecule claudin-18 A1 in both experimental colitis and ulcerative colitis.Inflamm Bowel Dis. 2008 Dec;14(12):1652-9. doi: 10.1002/ibd.20695.
• [167] Vascular endothelial growth factor, endostatin levels and clinical features among patients with ulcerative colitis and irritable bowel syndrome and among healthy controls: a cross-sectional analytical study.Sao Paulo Med J. 2018 Nov-Dec;136(6):543-550. doi: 10.1590/1516-3180.2018.0274161118.
• [168] Activation of corticotropin-releasing factor receptor 1 aggravates dextran sodium sulphate-induced colitis in mice by promoting M1 macrophage polarization.Mol Med Rep. 2018 Jan;17(1):234-242. doi: 10.3892/mmr.2017.7909. Epub 2017 Oct 26.
• [169] Corticotropin-releasing factor receptor subtype 2 in human colonic mucosa: down-regulation in ulcerative colitis.World J Gastroenterol. 2013 Mar 7;19(9):1416-23. doi: 10.3748/wjg.v19.i9.1416.
• [170] An Inhibitor of Casein Kinase 1/ (PF670462) Prevents the Deterioration of Dextran Sodium Sulfate-induced Ulcerative Colitis Caused by UVB Eye Irradiation.Int J Biol Sci. 2018 Jun 2;14(9):992-999. doi: 10.7150/ijbs.24558. eCollection 2018.
• [171] Preventive Effect of Cardiotrophin-1 Administration before DSS-Induced Ulcerative Colitis in Mice.J Clin Med. 2019 Dec 1;8(12):2086. doi: 10.3390/jcm8122086.
• [172] The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis.J Pharmacol Exp Ther. 2019 Jun;369(3):311-317. doi: 10.1124/jpet.118.254268. Epub 2019 Mar 14.
• [173] Changes in the Pharmacokinetics of Phenytoin in Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice.Int J Toxicol. 2017 Nov/Dec;36(6):485-491. doi: 10.1177/1091581817735987. Epub 2017 Nov 12.
• [174] Serum derived from ulcerative colitis mouse changes the metabolism of the fluorescent substrate by P450 depending on the degree of disease progression.Chem Biol Interact. 2018 Jun 25;290:88-98. doi: 10.1016/j.cbi.2018.05.012. Epub 2018 May 26.
• [175] Complex TNF- B cell epitope MAP vaccine alleviates murine ulcerative colitis.Int J Mol Med. 2019 Sep;44(3):1106-1116. doi: 10.3892/ijmm.2019.4271. Epub 2019 Jul 8.
• [176] REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1 Inflammatory Response in Active Ulcerative Colitis.J Immunol. 2018 Jun 15;200(12):3950-3961. doi: 10.4049/jimmunol.1701643. Epub 2018 Apr 30.
• [177] From model cell line to in vivo gene expression: disease-related intestinal gene expression in IBD.Genes Immun. 2008 Apr;9(3):240-8. doi: 10.1038/gene.2008.11. Epub 2008 Mar 13.
• [178] Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients.Exp Hematol. 2019 Dec;80:36-41.e3. doi: 10.1016/j.exphem.2019.11.008. Epub 2019 Dec 5.
• [179] Altered pattern of tumor necrosis factor-alpha production in peripheral blood monocytes from Crohn's disease.World J Gastroenterol. 2016 Nov 7;22(41):9117-9126. doi: 10.3748/wjg.v22.i41.9117.
• [180] EED gene polymorphism in patients with colorectal cancer.Int J Biol Markers. 2013 Sep 27;28(3):274-9. doi: 10.5301/JBM.5000024.
• [181] Prolyl Hydroxylase Inhibition Mitigates Pouchitis.Inflamm Bowel Dis. 2020 Jan 6;26(2):192-205. doi: 10.1093/ibd/izz218.
• [182] Identification of bacteria from blood in febrile patients with ulcerative colitis by terminal restriction fragment length polymorphism profile analysis of 16S rRNA gene.Scand J Gastroenterol. 2008;43(4):423-30. doi: 10.1080/00365520701737229.
• [183] Bcl2L12 mediates effects of protease-activated receptor-2 on the pathogenesis of Th2-dominated responses of patients with ulcerative colitis.Arch Biochem Biophys. 2018 Nov 1;657:8-14. doi: 10.1016/j.abb.2018.09.003. Epub 2018 Sep 11.
• [184] Case Report: Acute Flair of Ulcerative Colitis during Pregnancy Is Still a Major Problem.Dig Dis. 2017;35(1-2):134-138. doi: 10.1159/000449094. Epub 2017 Feb 1.
• [185] Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis.Regul Pept. 2008 Apr 10;147(1-3):25-8. doi: 10.1016/j.regpep.2007.12.002. Epub 2007 Dec 15.
• [186] Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4.Gastroenterology. 2009 Dec;137(6):2018-29.e1-3. doi: 10.1053/j.gastro.2009.06.047. Epub 2009 Jun 23.
• [187] Transcriptomic Analysis and High-dimensional Phenotypic Mapping of Mononuclear Phagocytes in Mesenteric Lymph Nodes Reveal Differences Between Ulcerative Colitis and Crohn's Disease.J Crohns Colitis. 2020 Mar 13;14(3):393-405. doi: 10.1093/ecco-jcc/jjz156.
• [188] IgG and Fc Receptors in Intestinal Immunity and Inflammation.Front Immunol. 2019 Apr 12;10:805. doi: 10.3389/fimmu.2019.00805. eCollection 2019.
• [189] A unique polysaccharide from Hericium erinaceus mycelium ameliorates acetic acid-induced ulcerative colitis rats by modulating the composition of the gut microbiota, short chain fatty acids levels and GPR41/43 respectors.Int Immunopharmacol. 2019 Jun;71:411-422. doi: 10.1016/j.intimp.2019.02.038. Epub 2019 May 3.
• [190] Ulcerative colitis-specific delivery of keratinocyte growth factor by neutrophils-simulated liposomes facilitates the morphologic and functional recovery of the damaged colon through alleviating the inflammation.J Control Release. 2019 Apr 10;299:90-106. doi: 10.1016/j.jconrel.2019.02.034. Epub 2019 Feb 23.
• [191] Identification of a new WASP and FKBP-like (WAFL) protein in inflammatory bowel disease: a potential marker gene for ulcerative colitis.Int J Colorectal Dis. 2008 Oct;23(10):921-30. doi: 10.1007/s00384-008-0527-8. Epub 2008 Jul 25.
• [192] The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis.Exp Mol Med. 2013 Sep 13;45(9):e40. doi: 10.1038/emm.2013.77.
• [193] Association of Ulcerative Colitis with FUT2 and FUT3 Polymorphisms in Patients from Southeast China.PLoS One. 2016 Jan 14;11(1):e0146557. doi: 10.1371/journal.pone.0146557. eCollection 2016.
• [194] Identification of Ten Additional Susceptibility Loci for Ulcerative Colitis Through Immunochip Analysis in Koreans.Inflamm Bowel Dis. 2016 Jan;22(1):13-9. doi: 10.1097/MIB.0000000000000584.
• [195] The EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitis.Mucosal Immunol. 2019 May;12(3):733-745. doi: 10.1038/s41385-019-0140-x. Epub 2019 Feb 11.
• [196] Enhanced Contribution of HLA in Pediatric Onset Ulcerative Colitis.Inflamm Bowel Dis. 2018 Mar 19;24(4):829-838. doi: 10.1093/ibd/izx084.
• [197] G protein-coupled receptor 55 (GPR55) expresses differently in patients with Crohn's disease and ulcerative colitis.Scand J Gastroenterol. 2017 Jun-Jul;52(6-7):711-715. doi: 10.1080/00365521.2017.1298834. Epub 2017 Mar 8.
• [198] The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease.Scand J Gastroenterol. 2015;50(10):1241-52. doi: 10.3109/00365521.2015.1038849. Epub 2015 May 15.
• [199] Ectopic expression of OX1R in ulcerative colitis mediates anti-inflammatory effect of orexin-A.Biochim Biophys Acta Mol Basis Dis. 2018 Nov;1864(11):3618-3628. doi: 10.1016/j.bbadis.2018.08.023. Epub 2018 Aug 18.
• [200] Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.Gastroenterology. 2015 Nov;149(6):1575-1586. doi: 10.1053/j.gastro.2015.07.065. Epub 2015 Aug 14.
• [201] HLA-G is expressed in intestinal samples of ulcerative colitis and Crohn's disease patients and HLA-G5 expression is differentially correlated with TNF and IL-10 cytokine expression.Hum Immunol. 2018 Jun;79(6):477-484. doi: 10.1016/j.humimm.2018.03.006. Epub 2018 Mar 26.
• [202] Role of hepatocyte nuclear factor 4-alpha in gastrointestinal and liver diseases.World J Gastroenterol. 2019 Aug 14;25(30):4074-4091. doi: 10.3748/wjg.v25.i30.4074.
• [203] Discovery of a Potent Grp94 Selective Inhibitor with Anti-Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis.J Med Chem. 2018 Nov 8;61(21):9513-9533. doi: 10.1021/acs.jmedchem.8b00800. Epub 2018 Oct 26.
• [204] Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis.World J Gastroenterol. 2016 Mar 28;22(12):3451-9. doi: 10.3748/wjg.v22.i12.3451.
• [205] Low HtrA1 expression in patients with longstanding ulcerative colitis and colorectal cancer.Oncol Rep. 2017 Jul;38(1):418-426. doi: 10.3892/or.2017.5700. Epub 2017 Jun 6.
• [206] Association of celiac disease genes with inflammatory bowel disease in Finnish and Swedish patients.Genes Immun. 2012 Sep;13(6):474-80. doi: 10.1038/gene.2012.21. Epub 2012 May 17.
• [207] Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy.Pharmacogenomics J. 2018 Jan;18(1):87-97. doi: 10.1038/tpj.2016.84. Epub 2017 Jan 31.
• [208] IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflamm Bowel Dis. 2013 Jan;19(1):115-23. doi: 10.1002/ibd.22974.
• [209] The expression analysis of Fra-1 gene and IL-11 protein in Iranian patients with ulcerative colitis.BMC Immunol. 2018 Jun 18;19(1):17. doi: 10.1186/s12865-018-0257-9.
• [210] How to conduct research of rare autoimmune diseases.Mod Rheumatol. 2018 Sep;28(5):766-769. doi: 10.1080/14397595.2018.1465632. Epub 2018 May 22.
• [211] Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients.Gastroenterology. 2017 May;152(6):1345-1357.e7. doi: 10.1053/j.gastro.2017.01.016. Epub 2017 Jan 26.
• [212] Interleukin-15 receptor expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab.Immunology. 2013 Jan;138(1):47-56. doi: 10.1111/imm.12014.
• [213] Increased expression of IL-16 in inflammatory bowel disease.Gut. 2001 Mar;48(3):326-32. doi: 10.1136/gut.48.3.326.
• [214] Genome-wide association identifies multiple ulcerative colitis susceptibility loci.Nat Genet. 2010 Apr;42(4):332-7. doi: 10.1038/ng.549. Epub 2010 Mar 14.
• [215] The Stimulation of Macrophages with TLR Ligands Supports Increased IL-19 Expression in Inflammatory Bowel Disease Patients and in Colitis Models.J Immunol. 2017 Oct 1;199(7):2570-2584. doi: 10.4049/jimmunol.1700350. Epub 2017 Sep 1.
• [216] Role of the IL-33/ST2L axis in colorectal cancer progression.Cell Immunol. 2019 Sep;343:103740. doi: 10.1016/j.cellimm.2017.12.014. Epub 2018 Jan 9.
• [217] IL-36 signaling controls the induced regulatory T cell-Th9 cell balance via NFB activation and STAT transcription factors.Mucosal Immunol. 2017 Nov;10(6):1455-1467. doi: 10.1038/mi.2017.21. Epub 2017 Mar 22.
• [218] Genetic polymorphisms of interleukin 20 (IL-20) in patients with ulcerative colitis.Immunol Lett. 2013 Jan;149(1-2):50-3. doi: 10.1016/j.imlet.2012.11.008. Epub 2012 Nov 23.
• [219] Interleukin (IL)-22 from IL-20 Subfamily of Cytokines Induces Colonic Epithelial Cell Proliferation Predominantly through ERK1/2 Pathway.Int J Mol Sci. 2019 Jul 15;20(14):3468. doi: 10.3390/ijms20143468.
• [220] Characterization and Expansion of Autologous GMP-ready Regulatory T Cells for TREG-based Cell Therapy in Patients with Ulcerative Colitis.Inflamm Bowel Dis. 2017 Aug;23(8):1348-1359. doi: 10.1097/MIB.0000000000001192.
• [221] Acetylcholinesterase Inhibitor Pyridostigmine Bromide Attenuates Gut Pathology and Bacterial Dysbiosis in a Murine Model of Ulcerative Colitis.Dig Dis Sci. 2020 Jan;65(1):141-149. doi: 10.1007/s10620-019-05838-6. Epub 2019 Oct 23.
• [222] SHIP1 Deficiency in Inflammatory Bowel Disease Is Associated With Severe Crohn's Disease and Peripheral T Cell Reduction.Front Immunol. 2018 May 22;9:1100. doi: 10.3389/fimmu.2018.01100. eCollection 2018.
• [223] Systems pharmacology approach reveals the antiinflammatory effects of Ampelopsis grossedentata on dextran sodium sulfate-induced colitis.World J Gastroenterol. 2018 Apr 7;24(13):1398-1409. doi: 10.3748/wjg.v24.i13.1398.
• [224] Altered expression of Tumor Necrosis Factor Alpha -Induced Protein 3 correlates with disease severity in Ulcerative Colitis.Sci Rep. 2017 Aug 25;7(1):9420. doi: 10.1038/s41598-017-09796-9.
• [225] CD103+ Dendritic Cell Function Is Altered in the Colons of Patients with Ulcerative Colitis.Inflamm Bowel Dis. 2017 Sep;23(9):1524-1534. doi: 10.1097/MIB.0000000000001204.
• [226] Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months.Rev Esp Enferm Dig. 2018 Sep;110(9):564-570. doi: 10.17235/reed.2018.5368/2017.
• [227] Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease.PLoS One. 2018 Mar 29;13(3):e0194222. doi: 10.1371/journal.pone.0194222. eCollection 2018.
• [228] Association between KIR-HLA combination and ulcerative colitis and Crohn's disease in a Japanese population.PLoS One. 2018 Apr 12;13(4):e0195778. doi: 10.1371/journal.pone.0195778. eCollection 2018.
• [229] Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility.Genes Immun. 2006 Oct;7(7):576-82. doi: 10.1038/sj.gene.6364333. Epub 2006 Aug 24.
• [230] Regulatory role of NKG2D+ NK cells in intestinal lamina propria by secreting double-edged Th1 cytokines in ulcerative colitis.Oncotarget. 2017 Oct 30;8(58):98945-98952. doi: 10.18632/oncotarget.22132. eCollection 2017 Nov 17.
• [231] Restricted V(H) gene usage in lamina propria B cells producing anticolon antibody from patients with ulcerative colitis.Gastroenterology. 2001 Jul;121(1):15-23. doi: 10.1053/gast.2001.25477.
• [232] The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.Inflamm Bowel Dis. 2020 Mar 4;26(4):643-652. doi: 10.1093/ibd/izz094.
• [233] Predicting ulcerative colitis-associated colorectal cancer using reverse-transcription polymerase chain reaction analysis.Clin Colorectal Cancer. 2011 Jun;10(2):134-41. doi: 10.1016/j.clcc.2011.03.011. Epub 2011 Apr 22.
• [234] Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IB.PLoS One. 2012;7(12):e52782. doi: 10.1371/journal.pone.0052782. Epub 2012 Dec 28.
• [235] miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes.Inflamm Bowel Dis. 2012 Jan;18(1):94-100. doi: 10.1002/ibd.21742. Epub 2011 May 6.
• [236] Associations between functional polymorphisms in the NFB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease.Pharmacogenomics J. 2014 Dec;14(6):526-34. doi: 10.1038/tpj.2014.19. Epub 2014 Apr 29.
• [237] Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease?.Mucosal Immunol. 2012 Mar;5(2):129-39. doi: 10.1038/mi.2011.57. Epub 2011 Dec 7.
• [238] Inherited deficiency of mannan-binding lectin-associated serine protease 2.N Engl J Med. 2003 Aug 7;349(6):554-60. doi: 10.1056/NEJMoa022836.
• [239] Myc-Associated Zinc Finger Protein Regulates the Proinflammatory Response in Colitis and Colon Cancer via STAT3 Signaling.Mol Cell Biol. 2018 Oct 29;38(22):e00386-18. doi: 10.1128/MCB.00386-18. Print 2018 Nov 15.
• [240] Association between functional promoter polymorphisms of macrophage migration inhibitory factor (MIF) gene and ulcerative colitis in Japan.Cytokine. 2010 Aug;51(2):173-7. doi: 10.1016/j.cyto.2010.05.003.
• [241] Transcriptional analysis of left-sided colitis, pancolitis, and ulcerative colitis-associated dysplasia.Inflamm Bowel Dis. 2014 Dec;20(12):2340-52. doi: 10.1097/MIB.0000000000000235.
• [242] Haplotype analyses of DNA repair gene polymorphisms and their role in ulcerative colitis.PLoS One. 2014 Sep 23;9(9):e108562. doi: 10.1371/journal.pone.0108562. eCollection 2014.
• [243] Association of hepatocyte-derived growth factor receptor/caudal type homeobox 2 co-expression with mucosal regeneration in active ulcerative colitis.World J Gastroenterol. 2015 Jul 28;21(28):8569-79. doi: 10.3748/wjg.v21.i28.8569.
• [244] Effect of BSN-MST1 locus on inflammatory bowel disease and multiple sclerosis susceptibility.Genes Immun. 2009 Oct;10(7):631-5. doi: 10.1038/gene.2009.56. Epub 2009 Aug 6.
• [245] Associations of distinct variants of the intestinal mucin gene MUC3A with ulcerative colitis and Crohn's disease.J Hum Genet. 2001;46(1):5-20. doi: 10.1007/s100380170118.
• [246] Mucin gene expression in the intestine of ulcerative colitis patients: a systematic review and meta-analysis.Eur J Gastroenterol Hepatol. 2016 Nov;28(11):1241-5. doi: 10.1097/MEG.0000000000000707.
• [247] Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids.PLoS One. 2012;7(5):e37729. doi: 10.1371/journal.pone.0037729. Epub 2012 May 25.
• [248] Never in mitosis gene A-related kinase 6 and aurora kinase A: New gene biomarkers in the conversion from ulcerative colitis to colorectal cancer.Oncol Rep. 2015 Oct;34(4):1905-14. doi: 10.3892/or.2015.4187. Epub 2015 Aug 10.
• [249] Systematic association mapping identifies NELL1 as a novel IBD disease gene.PLoS One. 2007 Aug 8;2(8):e691. doi: 10.1371/journal.pone.0000691.
• [250] Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG).Scand J Gastroenterol. 2017 Feb;52(2):216-221. doi: 10.1080/00365521.2016.1246605. Epub 2016 Oct 31.
• [251] Cancer-predicting transcriptomic and epigenetic signatures revealed for ulcerative colitis in patient-derived epithelial organoids.Oncotarget. 2018 Jun 19;9(47):28717-28730. doi: 10.18632/oncotarget.25617. eCollection 2018 Jun 19.
• [252] Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses.Cancer Res. 2018 Aug 1;78(15):4303-4315. doi: 10.1158/0008-5472.CAN-18-0116. Epub 2018 May 31.
• [253] Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon.Mucosal Immunol. 2017 Jul;10(4):887-900. doi: 10.1038/mi.2016.95. Epub 2016 Nov 2.
• [254] A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis.Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):12023-7. doi: 10.1073/pnas.1004982107. Epub 2010 Jun 14.
• [255] Relationship between the platelet activating factor acetylhydrolase gene and intractability of ulcerative colitis.Dis Colon Rectum. 2002 Mar;45(3):389-93. doi: 10.1007/s10350-004-6188-y.
• [256] Oral engineered Bifidobacterium longum expressing rhMnSOD to suppress experimental colitis.Int Immunopharmacol. 2018 Apr;57:25-32. doi: 10.1016/j.intimp.2018.02.004. Epub 2018 Feb 15.
• [257] COX-1/PGE(2)/EP4 alleviates mucosal injury by upregulating -arr1-mediated Akt signaling in colitis.Sci Rep. 2017 Apr 21;7(1):1055. doi: 10.1038/s41598-017-01169-6.
• [258] The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort.Digestion. 2016;93(3):182-92. doi: 10.1159/000444479. Epub 2016 Feb 27.
• [259] Apical junction complex proteins and ulcerative colitis: a focus on the PTPRS gene.Expert Rev Mol Diagn. 2008 Jul;8(4):465-77. doi: 10.1586/14737159.8.4.465.
• [260] Recent insights into the genetics of inflammatory bowel disease.Gastroenterology. 2011 May;140(6):1704-12. doi: 10.1053/j.gastro.2011.02.046.
• [261] Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation.Cold Spring Harb Perspect Biol. 2020 Mar 2;12(3):a036368. doi: 10.1101/cshperspect.a036368.
• [262] High Adherence to Surveillance Guidelines in Inflammatory Bowel Disease Patients Results in Low Colorectal Cancer and Dysplasia Rates, While Rates of Dysplasia are Low Before the Suggested Onset of Surveillance.J Crohns Colitis. 2019 Sep 27;13(10):1343-1350. doi: 10.1093/ecco-jcc/jjz066.
• [263] Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.PLoS One. 2018 Apr 2;13(4):e0193236. doi: 10.1371/journal.pone.0193236. eCollection 2018.
• [264] Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis.J Intern Med. 2018 Jun;283(6):568-577. doi: 10.1111/joim.12744. Epub 2018 Mar 24.
• [265] Inverse Association Between Circulating Monocyte-Platelet Complexes and Inflammation in Ulcerative Colitis Patients.Inflamm Bowel Dis. 2018 Mar 19;24(4):818-828. doi: 10.1093/ibd/izx106.
• [266] Increased DMT1 and FPN1 expression with enhanced iron absorption in ulcerative colitis human colon.Am J Physiol Cell Physiol. 2020 Feb 1;318(2):C263-C271. doi: 10.1152/ajpcell.00128.2019. Epub 2019 Nov 13.
• [267] A PepT1 mediated medicinal nano-system for targeted delivery of cyclosporine A to alleviate acute severe ulcerative colitis.Biomater Sci. 2019 Oct 1;7(10):4299-4309. doi: 10.1039/c9bm00925f. Epub 2019 Aug 13.
• [268] ATF4 Deficiency Promotes Intestinal Inflammation in Mice by Reducing Uptake of Glutamine and Expression of Antimicrobial Peptides.Gastroenterology. 2019 Mar;156(4):1098-1111. doi: 10.1053/j.gastro.2018.11.033. Epub 2018 Nov 16.
• [269] Polymorphisms in the sodium-dependent ascorbate transporter gene SLC23A1 are associated with susceptibility to Crohn disease.Am J Clin Nutr. 2014 Feb;99(2):378-83. doi: 10.3945/ajcn.113.068015. Epub 2013 Nov 27.
• [270] Evaluating the Association of Common Variants of the SLC44A4 Gene with Ulcerative Colitis Susceptibility in the Han Chinese Population.Genet Test Mol Biomarkers. 2017 Sep;21(9):555-559. doi: 10.1089/gtmb.2017.0010. Epub 2017 Jul 28.
• [271] Real-time PCR quantification analysis of five mucosal transcripts in patients with Crohn's disease.Eur J Gastroenterol Hepatol. 2008 Apr;20(4):290-6. doi: 10.1097/MEG.0b013e3282f3557c.
• [272] Association of Serotonin Transporter Promoter Polymorphism (5-HTTLPR) with Microscopic Colitis and Ulcerative Colitis.Dig Dis Sci. 2015 Apr;60(4):887-94. doi: 10.1007/s10620-014-3482-y. Epub 2014 Dec 23.
• [273] Mechanism of regulation of Na-H exchanger in inflammatory bowel disease: role of TLR-4 signaling mechanism.Dig Dis Sci. 2011 Jun;56(6):1656-62. doi: 10.1007/s10620-010-1524-7. Epub 2011 Jan 8.
• [274] Preserved Na(+)/H(+) exchanger isoform 3 expression and localization, but decreased NHE3 function indicate regulatory sodium transport defect in ulcerative colitis.Inflamm Bowel Dis. 2010 Jul;16(7):1149-61. doi: 10.1002/ibd.21183.
• [275] Genetic variants of SMAD2/3/4/7 are associated with susceptibility to ulcerative colitis in a Japanese genetic background.Immunol Lett. 2019 Mar;207:64-72. doi: 10.1016/j.imlet.2019.01.007. Epub 2019 Jan 14.
• [276] High suppressor of cytokine signaling-3 expression impairs STAT3-dependent protective effects of interleukin-22 in ulcerative colitis in remission.Inflamm Bowel Dis. 2015 Feb;21(2):241-50. doi: 10.1097/MIB.0000000000000267.
• [277] Time-to-reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease.J Pediatr Gastroenterol Nutr. 2019 Oct;69(4):466-473. doi: 10.1097/MPG.0000000000002458.
• [278] Overexpression of microRNA-495 improves the intestinal mucosal barrier function by targeting STAT3 via inhibition of the JAK/STAT3 signaling pathway in a mouse model of ulcerative colitis.Pathol Res Pract. 2018 Jan;214(1):151-162. doi: 10.1016/j.prp.2017.10.003. Epub 2017 Oct 12.
• [279] NDR1 protein kinase promotes IL-17- and TNF--mediated inflammation by competitively binding TRAF3.EMBO Rep. 2017 Apr;18(4):586-602. doi: 10.15252/embr.201642140. Epub 2017 Feb 20.
• [280] Pharmacological targeting of SPAK kinase in disorders of impaired epithelial transport.Expert Opin Ther Targets. 2017 Aug;21(8):795-804. doi: 10.1080/14728222.2017.1351949. Epub 2017 Jul 12.
• [281] Structural basis of species-selective antagonist binding to the succinate receptor.Nature. 2019 Oct;574(7779):581-585. doi: 10.1038/s41586-019-1663-8. Epub 2019 Oct 23.
• [282] Trace amine associated receptor 1 (TAAR1) expression and modulation of inflammatory cytokine production in mouse bone marrow-derived macrophages: a novel mechanism for inflammation in ulcerative colitis.Immunopharmacol Immunotoxicol. 2019 Dec;41(6):577-585. doi: 10.1080/08923973.2019.1672178. Epub 2019 Oct 1.
• [283] Redox modulatory protective effects of -3 fatty acids rich fish oil against experimental colitis.Toxicol Mech Methods. 2019 May;29(4):244-254. doi: 10.1080/15376516.2018.1553220. Epub 2019 Jan 16.
• [284] Polymorphisms in the Toll-Like Receptor and the IL-23/IL-17 Pathways Were Associated with Susceptibility to Inflammatory Bowel Disease in a Danish Cohort.PLoS One. 2015 Dec 23;10(12):e0145302. doi: 10.1371/journal.pone.0145302. eCollection 2015.
• [285] Enteric Viruses Ameliorate Gut Inflammation via Toll-like Receptor 3 and Toll-like Receptor 7-Mediated Interferon- Production.Immunity. 2016 Apr 19;44(4):889-900. doi: 10.1016/j.immuni.2016.03.009. Epub 2016 Apr 12.
• [286] Expression and function of toll-like receptor 8 and Tollip in colonic epithelial cells from patients with inflammatory bowel disease.Scand J Gastroenterol. 2009;44(2):195-204. doi: 10.1080/00365520802495529.
• [287] PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.PLoS One. 2018 Aug 30;13(8):e0202942. doi: 10.1371/journal.pone.0202942. eCollection 2018.
• [288] Identification of single nucleotide polymorphisms in the TNFRSF17 gene and their association with gastrointestinal disorders.Mol Cells. 2010 Jan;29(1):21-8. doi: 10.1007/s10059-010-0002-6. Epub 2009 Dec 7.
• [289] Dysregulated Up-Frameshift Protein 1 Promotes Ulcerative Colitis Pathogenesis Through the TNFR1-NF-B/MAPKs Pathway.Dig Dis Sci. 2018 Oct;63(10):2593-2603. doi: 10.1007/s10620-018-5171-8. Epub 2018 Jun 29.
• [290] Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.Aliment Pharmacol Ther. 2004 Aug 1;20(3):303-10. doi: 10.1111/j.1365-2036.2004.01946.x.
• [291] Diagnostic value of fecal B cell activating factor in patients with abdominal discomfort.Clin Exp Immunol. 2019 Nov;198(2):131-140. doi: 10.1111/cei.13350. Epub 2019 Aug 5.
• [292] Involvement of Activated Cdc42 Kinase1 in Colitis and Colorectal Neoplasms.Med Sci Monit. 2016 Dec 7;22:4794-4802. doi: 10.12659/msm.902274.
• [293] Evaluation of Melatonin Secretion and Metabolism Exponents in Patients with Ulcerative and Lymphocytic Colitis.Molecules. 2018 Jan 29;23(2):272. doi: 10.3390/molecules23020272.
• [294] The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients.Pharmacol Res. 2019 Nov;149:104464. doi: 10.1016/j.phrs.2019.104464. Epub 2019 Sep 22.
• [295] Oral administration of curcumin attenuates visceral hyperalgesia through inhibiting phosphorylation of TRPV1 in rat model of ulcerative colitis.Mol Pain. 2017 Jan-Dec;13:1744806917726416. doi: 10.1177/1744806917726416.
• [296] Expression Profiling of the Transient Receptor Potential Vanilloid (TRPV) Channels 1, 2, 3 and 4 in Mucosal Epithelium of Human Ulcerative Colitis.Cells. 2018 Jun 15;7(6):61. doi: 10.3390/cells7060061.
• [297] Macrophages Inability to Mediate Adherent-Invasive E. coli Replication is Linked to Autophagy in Crohn's Disease Patients.Cells. 2019 Nov 5;8(11):1394. doi: 10.3390/cells8111394.
• [298] [The effects of anti-inflammatory on activation of nuclear factor-kappaB and expression of cell adhesion molecules in patients with ulcerative colitis]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2004 Oct;21(5):732-6.
• [299] Association of ZAP70 and PTPN6, but Not BANK1 or CLEC2D, with inflammatory bowel disease in the Tunisian population.Genet Test Mol Biomarkers. 2013 Apr;17(4):321-6. doi: 10.1089/gtmb.2012.0372. Epub 2013 Feb 13.
• [300] Increased expression of chemokine receptor CCR3 and its ligands in ulcerative colitis: the role of colonic epithelial cells in in vitro studies.Clin Exp Immunol. 2010 Nov;162(2):337-47. doi: 10.1111/j.1365-2249.2010.04248.x.
• [301] IL-1R2 deficiency suppresses dextran sodium sulfate-induced colitis in mice via regulation of microbiota.Biochem Biophys Res Commun. 2018 Feb 12;496(3):934-940. doi: 10.1016/j.bbrc.2018.01.116. Epub 2018 Feb 2.
• [302] New bioinformatics approach to analyze gene expressions and signaling pathways reveals unique purine gene dysregulation profiles that distinguish between CD and UC.Inflamm Bowel Dis. 2009 Jul;15(7):971-84. doi: 10.1002/ibd.20893.
• [303] Single nucleotide polymorphisms in C-type lectin genes, clustered in the IBD2 and IBD6 susceptibility loci, may play a role in the pathogenesis of inflammatory bowel diseases.Eur J Gastroenterol Hepatol. 2012 Aug;24(8):965-70. doi: 10.1097/MEG.0b013e328354f3d5.
• [304] Fusobacterium nucleatum facilitates ulcerative colitis through activating IL-17F signaling to NF-B via the upregulation of CARD3 expression.J Pathol. 2020 Feb;250(2):170-182. doi: 10.1002/path.5358. Epub 2019 Dec 2.
• [305] Sphk1 promotes ulcerative colitis via activating JAK2/STAT3 signaling pathway.Hum Cell. 2020 Jan;33(1):57-66. doi: 10.1007/s13577-019-00283-z. Epub 2019 Oct 12.
• [306] Altered mRNA expression of telomere binding proteins (TPP1, POT1, RAP1, TRF1 and TRF2) in ulcerative colitis and Crohn's disease.Dig Liver Dis. 2010 Aug;42(8):544-8. doi: 10.1016/j.dld.2009.12.005. Epub 2010 Jan 12.
• [307] Associations between NRAMP1 Polymorphisms and Susceptibility to Ulcerative Colitis/Crohn's Disease: A Meta-Analysis.Immunol Invest. 2016;45(3):255-70. doi: 10.3109/08820139.2016.1149191. Epub 2016 Mar 28.
• [308] Single-nucleotide polymorphisms in SLC22A23 are associated with ulcerative colitis in a Canadian white cohort.Am J Clin Nutr. 2014 Jul;100(1):289-94. doi: 10.3945/ajcn.113.080549. Epub 2014 Apr 16.
• [309] Association of the OCTN1/1672T variant with increased risk for colorectal cancer in young individuals and ulcerative colitis patients.Inflamm Bowel Dis. 2012 Mar;18(3):439-48. doi: 10.1002/ibd.21814. Epub 2011 Jul 26.
• [310] Association of ulcerative colitis with solute-linked carrier family 26 member A3 gene polymorphisms and its expression in colonic tissues in Chinese patients.Int J Colorectal Dis. 2018 Sep;33(9):1169-1172. doi: 10.1007/s00384-018-3097-4. Epub 2018 May 31.
• [311] Catestatin Regulates Epithelial Cell Dynamics to Improve Intestinal Inflammation.Vaccines (Basel). 2018 Sep 20;6(4):67. doi: 10.3390/vaccines6040067.
• [312] A systematic review of the role of DNA methylation on inflammatory genes in ulcerative colitis.Epigenomics. 2016 May;8(5):667-84. doi: 10.2217/epi-2016-0006. Epub 2016 Apr 20.
• [313] Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer.Am J Gastroenterol. 2010 Jul;105(7):1610-9. doi: 10.1038/ajg.2010.22. Epub 2010 Feb 16.
• [314] The regulatory role of Nrf2 in antioxidants phase2 enzymes and IL-17A expression in patients with ulcerative colitis.Pathol Res Pract. 2018 Aug;214(8):1149-1155. doi: 10.1016/j.prp.2018.06.001. Epub 2018 Jun 23.
• [315] Association of Glutathione S-Transferase M1 null genotype with inflammatory bowel diseases: A systematic review and meta-analysis.Medicine (Baltimore). 2019 Nov;98(44):e17722. doi: 10.1097/MD.0000000000017722.
• [316] A Molecular Targeted Immunotherapeutic Strategy for Ulcerative Colitis via Dual-targeting Nanoparticles Delivering miR-146b to Intestinal Macrophages.J Crohns Colitis. 2019 Mar 30;13(4):482-494. doi: 10.1093/ecco-jcc/jjy181.
• [317] Crohn's disease in Japanese is associated with a SNP-haplotype of N-acetyltransferase 2 gene.World J Gastroenterol. 2005 Aug 21;11(31):4833-7. doi: 10.3748/wjg.v11.i31.4833.
• [318] NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol. 2008 Mar;46(3):259-65.
• [319] Impaired self-renewal and increased colitis and dysplastic lesions in colonic mucosa of AKR1B8-deficient mice.Clin Cancer Res. 2015 Mar 15;21(6):1466-76. doi: 10.1158/1078-0432.CCR-14-2072. Epub 2014 Dec 23.
• [320] Evaluation of enterochromaffin cells and melatonin secretion exponents in ulcerative colitis.World J Gastroenterol. 2013 Jun 21;19(23):3602-7. doi: 10.3748/wjg.v19.i23.3602.
• [321] Role of cytochrome P450 polymorphisms and functions in development of ulcerative colitis.World J Gastroenterol. 2019 Jun 21;25(23):2846-2862. doi: 10.3748/wjg.v25.i23.2846.
• [322] Genetic Polymorphisms in Fatty Acid Metabolism Modify the Association Between Dietary n3: n6 Intake and Risk of Ulcerative Colitis: A Prospective Cohort Study.Inflamm Bowel Dis. 2017 Nov;23(11):1898-1904. doi: 10.1097/MIB.0000000000001236.
• [323] The prolyl hydroxylase PHD3 identifies proinflammatory macrophages and its expression is regulated by activin A.J Immunol. 2012 Aug 15;189(4):1946-54. doi: 10.4049/jimmunol.1201064. Epub 2012 Jul 9.
• [324] A blood-based prognostic biomarker in IBD.Gut. 2019 Aug;68(8):1386-1395. doi: 10.1136/gutjnl-2019-318343. Epub 2019 Apr 27.
• [325] Inverse expression of prostaglandin E2-related enzymes highlights differences between diverticulitis and inflammatory bowel disease.Dig Dis Sci. 2015 May;60(5):1236-46. doi: 10.1007/s10620-014-3478-7. Epub 2015 Feb 11.
• [326] Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study.BMC Gastroenterol. 2018 Aug 1;18(1):120. doi: 10.1186/s12876-018-0853-4.
• [327] Hyperhomocysteinemia and related genetic polymorphisms correlate with ulcerative colitis in Chinese Han population in Central China [corrected].Cell Biochem Biophys. 2012 Jan;62(1):203-10. doi: 10.1007/s12013-011-9283-4.
• [328] Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.J Gastroenterol. 2018 Sep;53(9):1048-1064. doi: 10.1007/s00535-018-1480-0. Epub 2018 Jun 4.
• [329] Increased expression and cellular localization of spermine oxidase in ulcerative colitis and relationship to disease activity.Inflamm Bowel Dis. 2010 Sep;16(9):1557-66. doi: 10.1002/ibd.21224.
• [330] miR-155 targets Est-1 and induces ulcerative colitis via the IL-23/17/6-mediated Th17 pathway.Pathol Res Pract. 2017 Oct;213(10):1289-1295. doi: 10.1016/j.prp.2017.08.001. Epub 2017 Aug 25.
• [331] Elevation in Cell Cycle and Protein Metabolism Gene Transcription in Inactive Colonic Tissue From Icelandic Patients With Ulcerative Colitis.Inflamm Bowel Dis. 2019 Jan 10;25(2):317-327. doi: 10.1093/ibd/izy350.
• [332] Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials.BMJ Open. 2019 Jan 25;9(1):e024222. doi: 10.1136/bmjopen-2018-024222.
• [333] Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease.Ann N Y Acad Sci. 1998 Nov 17;859:149-59. doi: 10.1111/j.1749-6632.1998.tb11119.x.
• [334] A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population.Nat Genet. 2009 Dec;41(12):1325-9. doi: 10.1038/ng.482. Epub 2009 Nov 15.
• [335] Chitosan Ameliorates DSS-Induced Ulcerative Colitis Mice by Enhancing Intestinal Barrier Function and Improving Microflora.Int J Mol Sci. 2019 Nov 15;20(22):5751. doi: 10.3390/ijms20225751.
• [336] Inflammatory bowel disease is linked to 19p13 and associated with ICAM-1.Inflamm Bowel Dis. 2004 May;10(3):173-81. doi: 10.1097/00054725-200405000-00001.
• [337] Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes.Hum Mol Genet. 2001 Mar 1;10(5):445-56. doi: 10.1093/hmg/10.5.445.
• [338] Targeting Nrf2/HO-1 signaling by crocin: Role in attenuation of AA-induced ulcerative colitis in rats.Biomed Pharmacother. 2019 Feb;110:389-399. doi: 10.1016/j.biopha.2018.11.133. Epub 2018 Dec 5.
• [339] Interleukin-18 is increased only in a minority of patients with active Crohn's disease.Int J Colorectal Dis. 2007 Sep;22(9):1013-20. doi: 10.1007/s00384-007-0282-2. Epub 2007 Feb 21.
• [340] Immunohistochemical Studies on Galectin Expression in Colectomised Patients with Ulcerative Colitis. Biomed Res Int. 2016;2016:5989128.
• [341] Replication of genetic variation in the MYO9B gene in Crohn's disease.Hum Immunol. 2011 Jul;72(7):592-7. doi: 10.1016/j.humimm.2011.03.025. Epub 2011 Apr 12.
• [342] MEFV Gene-Related Enterocolitis Account for Some Cases Diagnosed as Inflammatory Bowel Disease Unclassified.Digestion. 2020;101(6):785-793. doi: 10.1159/000502640. Epub 2019 Sep 6.
• [343] Characterization of Mycobacterium paratuberculosis p36 antigen and its seroreactivities in Crohn's disease.Curr Microbiol. 1999 Aug;39(2):115-9. doi: 10.1007/s002849900430.
• [344] Deep Resequencing of Ulcerative Colitis-Associated Genes Identifies Novel Variants in Candidate Genes in the Korean Population.Inflamm Bowel Dis. 2018 Jul 12;24(8):1706-1717. doi: 10.1093/ibd/izy122.
• [345] Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL).Nat Genet. 2010 Apr;42(4):292-4. doi: 10.1038/ng.553. Epub 2010 Mar 14.
• [346] Profound loss of neprilysin accompanied by decreased levels of neuropeptides and increased CRP in ulcerative colitis.PLoS One. 2017 Dec 12;12(12):e0189526. doi: 10.1371/journal.pone.0189526. eCollection 2017.
• [347] Serum trefoil factor 3 predicts disease activity in patients with ulcerative colitis.Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):788-794. doi: 10.26355/eurrev_201901_16893.
• [348] Genetic predictors of medically refractory ulcerative colitis.Inflamm Bowel Dis. 2010 Nov;16(11):1830-40. doi: 10.1002/ibd.21293.
• [349] Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease.J Proteome Res. 2007 Mar;6(3):1114-25. doi: 10.1021/pr060433m.
• [350] Association study of MICA-TM polymorphism with inflammatory bowel disease in the South Tunisian population.Genet Test Mol Biomarkers. 2013 Aug;17(8):615-9. doi: 10.1089/gtmb.2012.0423. Epub 2013 Jul 3.
• [351] Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease.J Mol Med (Berl). 2006 Dec;84(12):1055-66. doi: 10.1007/s00109-006-0100-2. Epub 2006 Oct 21.
• [352] An SNP linkage scan identifies significant Crohn's disease loci on chromosomes 13q13.3 and, in Jewish families, on 1p35.2 and 3q29.Genes Immun. 2008 Mar;9(2):161-7. doi: 10.1038/sj.gene.6364460. Epub 2008 Jan 31.
• [353] The ATG16L1 risk allele associated with Crohn's disease results in a Rac1-dependent defect in dendritic cell migration that is corrected by thiopurines.Mucosal Immunol. 2017 Mar;10(2):352-360. doi: 10.1038/mi.2016.65. Epub 2016 Jul 20.
• [354] Altered expression of innate immunity genes in different intestinal sites of children with ulcerative colitis.Dig Liver Dis. 2010 Dec;42(12):848-53. doi: 10.1016/j.dld.2010.04.003. Epub 2010 May 7.
• [355] SALSA-A dance on a slippery floor with changing partners.Mol Immunol. 2017 Sep;89:100-110. doi: 10.1016/j.molimm.2017.05.029. Epub 2017 Jun 28.
• [356] Differential diagnosis of Crohn's disease using antibodies to glycoprotein 2 and Saccharomyces cerevisiae.Turk J Gastroenterol. 2019 Jan;30(1):21-27. doi: 10.5152/tjg.2018.18135.
• [357] Expression and Clinical Significance of Elafin in Inflammatory Bowel Disease.Inflamm Bowel Dis. 2017 Dec;23(12):2134-2141. doi: 10.1097/MIB.0000000000001252.
• [358] Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway.Inflamm Bowel Dis. 2012 Jun;18(6):1127-36. doi: 10.1002/ibd.21894. Epub 2011 Oct 10.
• [359] Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.PLoS One. 2017 Oct 13;12(10):e0185855. doi: 10.1371/journal.pone.0185855. eCollection 2017.
• [360] Actin related protein 3 (ARP3) promotes apoptosis of intestinal epithelial cells in ulcerative colitis.Pathol Res Pract. 2019 Feb;215(2):235-242. doi: 10.1016/j.prp.2018.10.011. Epub 2018 Oct 24.
• [361] The Microbial Composition of Bacteroidetes Species in Ulcerative Colitis Is Effectively Improved by Combination Therapy With Fecal Microbiota Transplantation and Antibiotics.Inflamm Bowel Dis. 2018 Nov 29;24(12):2590-2598. doi: 10.1093/ibd/izy266.
• [362] Neurotensin--regulated miR-133 is involved in proinflammatory signalling in human colonic epithelial cells and in experimental colitis.Gut. 2015 Jul;64(7):1095-104. doi: 10.1136/gutjnl-2014-307329. Epub 2014 Aug 11.
• [363] AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.Gastroenterology. 2019 Feb;156(3):769-808.e29. doi: 10.1053/j.gastro.2018.12.008. Epub 2018 Dec 18.
• [364] Dihydrotanshinone I, a natural product, ameliorates DSS-induced experimental ulcerative colitis in mice.Toxicol Appl Pharmacol. 2018 Apr 1;344:35-45. doi: 10.1016/j.taap.2018.02.018. Epub 2018 Feb 27.
• [365] Five mucosal transcripts of interest in ulcerative colitis identified by quantitative real-time PCR: a prospective study.BMC Gastroenterol. 2008 Aug 12;8:34. doi: 10.1186/1471-230X-8-34.
• [366] Altered Salivary Alpha-Amylase Secretion in Patients with Ulcerative Colitis.Gastroenterol Res Pract. 2018 May 24;2018:4203737. doi: 10.1155/2018/4203737. eCollection 2018.
• [367] EB1 protein alteration characterizes sporadic but not ulcerative colitis associated colorectal cancer.Oncotarget. 2017 Jul 4;8(33):54939-54950. doi: 10.18632/oncotarget.18978. eCollection 2017 Aug 15.
• [368] ANP32E, a Protein Involved in Steroid-Refractoriness in Ulcerative Colitis, Identified by a Systems Biology Approach.J Crohns Colitis. 2019 Mar 26;13(3):351-361. doi: 10.1093/ecco-jcc/jjy171.
• [369] Aquaporin 8 expression is reduced and regulated by microRNAs in patients with ulcerative colitis.Chin Med J (Engl). 2013;126(8):1532-7.
• [370] Accounting for eXentricities: analysis of the X chromosome in GWAS reveals X-linked genes implicated in autoimmune diseases.PLoS One. 2014 Dec 5;9(12):e113684. doi: 10.1371/journal.pone.0113684. eCollection 2014.
• [371] Molecular mechanisms by which casein glycomacropeptide maintains internal homeostasis in mice with experimental ulcerative colitis.PLoS One. 2017 Jul 10;12(7):e0181075. doi: 10.1371/journal.pone.0181075. eCollection 2017.
• [372] P53 germ line haplotypes associated with increased risk for colorectal cancer.Carcinogenesis. 1995 Jul;16(7):1461-4. doi: 10.1093/carcin/16.7.1461.
• [373] MiR-29a inhibited intestinal epithelial cells autophagy partly by decreasing ATG9A in ulcerative colitis.Anticancer Drugs. 2018 Aug;29(7):652-659. doi: 10.1097/CAD.0000000000000636.
• [374] Suppression of hath1 gene expression directly regulated by hes1 via notch signaling is associated with goblet cell depletion in ulcerative colitis.Inflamm Bowel Dis. 2011 Nov;17(11):2251-60. doi: 10.1002/ibd.21611. Epub 2011 Jan 6.
• [375] Colitis Is Effectively Ameliorated by ()-8-Acetonyl-dihydrocoptisine via the XBP1-NF-B Pathway.Front Pharmacol. 2017 Sep 5;8:619. doi: 10.3389/fphar.2017.00619. eCollection 2017.
• [376] Expression patterns common and unique to ulcerative colitis and celiac disease.Ann Hum Genet. 2019 Mar;83(2):86-94. doi: 10.1111/ahg.12293. Epub 2018 Nov 6.
• [377] Computational Prediction and Validation of BAHD1 as a Novel Molecule for Ulcerative Colitis.Sci Rep. 2015 Jul 17;5:12227. doi: 10.1038/srep12227.
• [378] Activation of NLRP3 Inflammasome in Inflammatory Bowel Disease: Differences Between Crohn's Disease and Ulcerative Colitis.Dig Dis Sci. 2017 Sep;62(9):2348-2356. doi: 10.1007/s10620-017-4609-8. Epub 2017 May 18.
• [379] Lineage-specific expression of bestrophin-2 and bestrophin-4 in human intestinal epithelial cells.PLoS One. 2013 Nov 5;8(11):e79693. doi: 10.1371/journal.pone.0079693. eCollection 2013.
• [380] Intestinal barrier tightening by a cell-penetrating antibody to Bin1, a candidate target for immunotherapy of ulcerative colitis.J Cell Biochem. 2019 Mar;120(3):4225-4237. doi: 10.1002/jcb.27716. Epub 2018 Sep 30.
• [381] Mucosal transcriptomics implicates under expression of BRINP3 in the pathogenesis of ulcerative colitis.Inflamm Bowel Dis. 2014 Oct;20(10):1802-12. doi: 10.1097/MIB.0000000000000169.
• [382] Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease.Inflamm Bowel Dis. 2010 Aug;16(8):1357-66. doi: 10.1002/ibd.21174.
• [383] BVES is required for maintenance of colonic epithelial integrity in experimental colitis by modifying intestinal permeability.Mucosal Immunol. 2018 Sep;11(5):1363-1374. doi: 10.1038/s41385-018-0043-2. Epub 2018 Jun 15.
• [384] Novel Associations Between Major Histocompatibility Complex and Pediatric-onset Inflammatory Bowel Disease.J Pediatr Gastroenterol Nutr. 2016 Apr;62(4):567-72. doi: 10.1097/MPG.0000000000000984.
• [385] Differential Intestinal Mucosa Transcriptomic Biomarkers for Crohn's Disease and Ulcerative Colitis.J Immunol Res. 2018 Oct 17;2018:9208274. doi: 10.1155/2018/9208274. eCollection 2018.
• [386] A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis.Hum Mol Genet. 2014 Dec 20;23(25):6927-34. doi: 10.1093/hmg/ddu398. Epub 2014 Jul 31.
• [387] Calcium/calmodulin-dependent protein kinase IV (CaMKIV) activation contributes to the pathogenesis of experimental colitis via inhibition of intestinal epithelial cell proliferation.FASEB J. 2019 Jan;33(1):1330-1346. doi: 10.1096/fj.201800535R. Epub 2018 Aug 16.
• [388] Association of CARD8 with inflammatory bowel disease in Koreans.J Hum Genet. 2011 Mar;56(3):217-23. doi: 10.1038/jhg.2010.170. Epub 2011 Jan 20.
• [389] Elevation of PRKCDBP, a novel transcriptional target of TNF-, and its downregulation by infliximab in patients with ulcerative colitis.Dig Dis Sci. 2014 Dec;59(12):2947-57. doi: 10.1007/s10620-014-3282-4. Epub 2014 Jul 23.
• [390] MTG16 is a tumor suppressor in colitis-associated carcinoma.JCI Insight. 2017 Aug 17;2(16):e78210. doi: 10.1172/jci.insight.78210. eCollection 2017 Aug 17.
• [391] CCDC88B is required for pathogenesis of inflammatory bowel disease.Nat Commun. 2017 Oct 13;8(1):932. doi: 10.1038/s41467-017-01381-y.
• [392] Randomised, Double-blind, Placebo-controlled Trial of CCR9-targeted Leukapheresis Treatment of Ulcerative Colitis Patients.J Crohns Colitis. 2017 May 1;11(5):534-542. doi: 10.1093/ecco-jcc/jjw196.
• [393] Regulation of eotaxin-3/CC chemokine ligand 26 expression by T helper type 2 cytokines in human colonic myofibroblasts.Clin Exp Immunol. 2013 Aug;173(2):323-31. doi: 10.1111/cei.12117.
• [394] Moxibustion treatment modulates the gut microbiota and immune function in a dextran sulphate sodium-induced colitis rat model.World J Gastroenterol. 2018 Jul 28;24(28):3130-3144. doi: 10.3748/wjg.v24.i28.3130.
• [395] miRNA-26b Overexpression in Ulcerative Colitis-associated Carcinogenesis.Inflamm Bowel Dis. 2015 Sep;21(9):2039-51. doi: 10.1097/MIB.0000000000000453.
• [396] Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.World J Gastroenterol. 2017 Dec 14;23(46):8235-8247. doi: 10.3748/wjg.v23.i46.8235.
• [397] IL-23 in inflammatory bowel diseases and colon cancer.Cytokine Growth Factor Rev. 2019 Feb;45:1-8. doi: 10.1016/j.cytogfr.2018.12.002. Epub 2018 Dec 12.
• [398] Caudal type homeobox 2 expression induced by leukocytapheresis might be associated with mucosal healing in ulcerative colitis.J Gastroenterol Hepatol. 2017 May;32(5):1032-1039. doi: 10.1111/jgh.13645.
• [399] miR-24 Is Elevated in Ulcerative Colitis Patients and Regulates Intestinal Epithelial Barrier Function.Am J Pathol. 2019 Sep;189(9):1763-1774. doi: 10.1016/j.ajpath.2019.05.018. Epub 2019 Jun 18.
• [400] Increase in chromogranin A- and serotonin-positive cells in pouch mucosa of patients with ulcerative colitis undergoing proctocolectomy.Dig Liver Dis. 2018 Nov;50(11):1205-1213. doi: 10.1016/j.dld.2018.04.021. Epub 2018 Apr 28.
• [401] MicroRNA 429 regulates the expression of CHMP5 in the inflammatory colitis and colorectal cancer cells.Inflamm Res. 2018 Dec;67(11-12):985-996. doi: 10.1007/s00011-018-1194-z. Epub 2018 Oct 17.
• [402] Relationship between CYP2A6 genetic polymorphism, as a marker of nicotine metabolism, and ulcerative colitis.Isr Med Assoc J. 2011 Feb;13(2):87-90.
• [403] GlcNAc6ST-1-mediated decoration of MAdCAM-1 protein with L-selectin ligand carbohydrates directs disease activity of ulcerative colitis.Inflamm Bowel Dis. 2009 May;15(5):697-706. doi: 10.1002/ibd.20827.
• [404] Comparison of Cytokine and Efflux Transporter Expression in Pediatric Versus Adult-onset Ulcerative Colitis.J Pediatr Gastroenterol Nutr. 2017 Jun;64(6):943-948. doi: 10.1097/MPG.0000000000001403.
• [405] CITED2 is activated in ulcerative colitis and induces p53-dependent apoptosis in response to butyric acid.J Gastroenterol. 2011 Mar;46(3):339-49. doi: 10.1007/s00535-010-0355-9. Epub 2010 Dec 17.
• [406] The response of human macrophages to -glucans depends on the inflammatory milieu.PLoS One. 2013 Apr 24;8(4):e62016. doi: 10.1371/journal.pone.0062016. Print 2013.
• [407] Contribution of Extracellular Matrix and Signal Mechanotransduction to Epithelial Cell Damage in Inflammatory Bowel Disease Patients: A Proteomic Study.Proteomics. 2017 Dec;17(23-24). doi: 10.1002/pmic.201700164. Epub 2017 Nov 29.
• [408] Copper metabolism domain-containing 1 represses genes that promote inflammation and protects mice from colitis and colitis-associated cancer.Gastroenterology. 2014 Jul;147(1):184-195.e3. doi: 10.1053/j.gastro.2014.04.007. Epub 2014 Apr 13.
• [409] Aberrant Brain Function in Active-Stage Ulcerative Colitis Patients: A Resting-State Functional MRI Study.Front Hum Neurosci. 2019 Apr 3;13:107. doi: 10.3389/fnhum.2019.00107. eCollection 2019.
• [410] Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases.Clin Chem Lab Med. 2017 Aug 28;55(10):1574-1581. doi: 10.1515/cclm-2016-1120.
• [411] DNA methylation profile of genes involved in inflammation and autoimmunity in inflammatory bowel disease.Medicine (Baltimore). 2014 Dec;93(28):e309. doi: 10.1097/MD.0000000000000309.
• [412] MicroRNA-141 Is Involved in Ulcerative Colitis Pathogenesis via Aiming at CXCL5.J Interferon Cytokine Res. 2017 Sep;37(9):415-420. doi: 10.1089/jir.2017.0019.
• [413] Effect of interleukin-17 on gene expression profile of fibroblasts from Crohn's disease patients.J Crohns Colitis. 2014 Oct;8(10):1208-16. doi: 10.1016/j.crohns.2014.02.009. Epub 2014 Mar 15.
• [414] Cytoglobin affects tumorigenesis and the expression of ulcerative colitis-associated genes under chemically induced colitis in mice.Sci Rep. 2018 May 2;8(1):6905. doi: 10.1038/s41598-018-24728-x.
• [415] NADPH oxidase p22phox gene expression in ulcerative colitis.Turk J Gastroenterol. 2014 Dec;25(6):634-8. doi: 10.5152/tjg.2014.5926.
• [416] Elevated d-2-hydroxyglutarate during colitis drives progression to colorectal cancer.Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1057-1062. doi: 10.1073/pnas.1712625115. Epub 2018 Jan 16.
• [417] Associations between markers of colorectal cancer stem cells, mutation, microRNA and the clinical features of ulcerative colitis.Colorectal Dis. 2016 Jun;18(6):O185-93. doi: 10.1111/codi.13371.
• [418] Human alpha defensin 5 is a candidate biomarker to delineate inflammatory bowel disease.PLoS One. 2017 Aug 17;12(8):e0179710. doi: 10.1371/journal.pone.0179710. eCollection 2017.
• [419] DEFB1 gene 5' untranslated region (UTR) polymorphisms are marginally involved in inflammatory bowel disease in south Brazilians.Int J Immunogenet. 2014 Apr;41(2):138-42. doi: 10.1111/iji.12089. Epub 2013 Sep 12.
• [420] Human -defensin 3 peptide is increased and redistributed in Crohn's ileitis.Inflamm Bowel Dis. 2013 Apr;19(5):942-53. doi: 10.1097/MIB.0b013e318280b11a.
• [421] beta-Defensin-3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis.Clin Exp Immunol. 2004 Aug;137(2):379-85. doi: 10.1111/j.1365-2249.2004.02543.x.
• [422] ACG Clinical Guideline: Ulcerative Colitis in Adults.Am J Gastroenterol. 2019 Mar;114(3):384-413. doi: 10.14309/ajg.0000000000000152.
• [423] No involvement of IgG autoantibodies against extracellular domains of desmoglein 2 in paraneoplastic pemphigus or inflammatory bowel diseases.J Dermatol Sci. 2003 Aug;32(2):137-41. doi: 10.1016/s0923-1811(03)00072-0.
• [424] Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature.J Clin Invest. 2014 Aug;124(8):3617-33. doi: 10.1172/JCI75436. Epub 2014 Jul 8.
• [425] DUOX2 and DUOXA2 form the predominant enzyme system capable of producing the reactive oxygen species H2O2 in active ulcerative colitis and are modulated by 5-aminosalicylic acid.Inflamm Bowel Dis. 2014 Mar;20(3):514-24. doi: 10.1097/01.MIB.0000442012.45038.0e.
• [426] Impact of Histological and Endoscopic Remissions on Clinical Recurrence and Recurrence-free Time in Ulcerative Colitis.Inflamm Bowel Dis. 2017 Dec;23(12):2238-2244. doi: 10.1097/MIB.0000000000001275.
• [427] Effects of alpha lipoic acid and its derivative "andrographolid-lipoic acid-1" on ulcerative colitis: A systematic review with meta-analysis of animal studies.J Cell Biochem. 2019 Apr;120(4):4766-4782. doi: 10.1002/jcb.27807. Epub 2018 Oct 26.
• [428] Analysis of Genes Involved in Ulcerative Colitis Activity and Tumorigenesis Through Systematic Mining of Gene Co-expression Networks.Front Physiol. 2019 May 31;10:662. doi: 10.3389/fphys.2019.00662. eCollection 2019.
• [429] Identifying candidate genes for discrimination of ulcerative colitis and Crohn's disease.Mol Biol Rep. 2014 Oct;41(10):6349-55. doi: 10.1007/s11033-014-3469-y. Epub 2014 Sep 3.
• [430] A Genome-Wide Methylation Approach Identifies a New Hypermethylated Gene Panel in Ulcerative Colitis.Int J Mol Sci. 2016 Aug 9;17(8):1291. doi: 10.3390/ijms17081291.
• [431] Impact of allele copy number of polymorphisms in FCGR3A and FCGR3B genes on susceptibility to ulcerative colitis.Inflamm Bowel Dis. 2013 Sep;19(10):2061-8. doi: 10.1097/MIB.0b013e318298118e.
• [432] Epistatic interaction between FCRL3 and MHC in Spanish patients with IBD.Tissue Antigens. 2007 Apr;69(4):313-7. doi: 10.1111/j.1399-0039.2007.00816.x.
• [433] Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction.PLoS Genet. 2008 Dec;4(12):e1000289. doi: 10.1371/journal.pgen.1000289. Epub 2008 Dec 5.
• [434] TAP gene transporter polymorphism in inflammatory bowel diseases.Scand J Gastroenterol. 1997 Oct;32(10):1022-7. doi: 10.3109/00365529709011219.
• [435] Association of Fucosyltransferase 2 Gene Variant with Inflammatory Bowel Diseases: A Meta-Analysis.Med Sci Monit. 2019 Jan 7;25:184-192. doi: 10.12659/MSM.911857.
• [436] Wnt pathway-related gene expression in inflammatory bowel disease.Dig Dis Sci. 2008 Apr;53(4):1013-9. doi: 10.1007/s10620-007-9973-3. Epub 2007 Oct 16.
• [437] Genetic analysis in a Dutch study sample identifies more ulcerative colitis susceptibility loci and shows their additive role in disease risk.Am J Gastroenterol. 2010 Feb;105(2):395-402. doi: 10.1038/ajg.2009.576. Epub 2009 Oct 27.
• [438] Identification of suitable reference microRNA for qPCR analysis in pediatric inflammatory bowel disease.Physiol Genomics. 2019 May 1;51(5):169-175. doi: 10.1152/physiolgenomics.00126.2018. Epub 2019 Apr 12.
• [439] Growth differentiation factor 11 ameliorates experimental colitis by inhibiting NLRP3 inflammasome activation.Am J Physiol Gastrointest Liver Physiol. 2018 Dec 1;315(6):G909-G920. doi: 10.1152/ajpgi.00159.2018. Epub 2018 Sep 6.
• [440] Identification of differentially expressed genes, associated functional terms pathways, and candidate diagnostic biomarkers in inflammatory bowel diseases by bioinformatics analysis.Exp Ther Med. 2019 Jul;18(1):278-288. doi: 10.3892/etm.2019.7541. Epub 2019 May 3.
• [441] Differential expression of GPR15 on T cells during ulcerative colitis.JCI Insight. 2017 Apr 20;2(8):e90585. doi: 10.1172/jci.insight.90585. eCollection 2017 Apr 20.
• [442] The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation.BMC Gastroenterol. 2019 Jan 7;19(1):2. doi: 10.1186/s12876-018-0922-8.
• [443] Potential of Lactobacillus plantarum ZDY2013 and Bifidobacterium bifidum WBIN03 in relieving colitis by gut microbiota, immune, and anti-oxidative stress.Can J Microbiol. 2018 May;64(5):327-337. doi: 10.1139/cjm-2017-0716. Epub 2018 Feb 5.
• [444] Genome-wide association studies of asthma indicate opposite immunopathogenesis direction from autoimmune diseases.J Allergy Clin Immunol. 2012 Oct;130(4):861-8.e7. doi: 10.1016/j.jaci.2012.04.041. Epub 2012 Jun 12.
• [445] Expression of guanylate cyclase-C, guanylin, and uroguanylin is downregulated proportionally to the ulcerative colitis disease activity index.Sci Rep. 2016 Apr 29;6:25034. doi: 10.1038/srep25034.
• [446] Association Between Response to Etrolizumab and Expression of Integrin E and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.Gastroenterology. 2016 Feb;150(2):477-87.e9. doi: 10.1053/j.gastro.2015.10.041. Epub 2015 Oct 30.
• [447] Granzyme M has a critical role in providing innate immune protection in ulcerative colitis.Cell Death Dis. 2016 Jul 21;7(7):e2302. doi: 10.1038/cddis.2016.215.
• [448] Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA.J Autoimmun. 2000 Feb;14(1):83-97. doi: 10.1006/jaut.1999.0340.
• [449] Nondysplastic Ulcerative Colitis Has High Levels of the Homologous Recombination Repair Protein NUCKS1 and Low Levels of the DNA Damage Marker Gamma-H2AX.Inflamm Bowel Dis. 2018 Feb 15;24(3):593-600. doi: 10.1093/ibd/izx071.
• [450] Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects.Hum Mol Genet. 2010 May 15;19(10):2059-67. doi: 10.1093/hmg/ddq078. Epub 2010 Feb 22.
• [451] An Intergenic Variant rs9268877 Between HLA-DRA and HLA-DRB Contributes to the Clinical Course and Long-term Outcome of Ulcerative Colitis.J Crohns Colitis. 2018 Aug 29;12(9):1113-1121. doi: 10.1093/ecco-jcc/jjy080.
• [452] Strong protective effect of DR3 against ulcerative colitis in the Spanish population.Am J Gastroenterol. 2007 Dec;102(12):2762-6. doi: 10.1111/j.1572-0241.2007.01487.x. Epub 2007 Aug 21.
• [453] Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis.Inflamm Bowel Dis. 2007 Jul;13(7):807-21. doi: 10.1002/ibd.20110.
• [454] Heat shock factor 2 levels are associated with the severity of ulcerative colitis.PLoS One. 2014 Feb 12;9(2):e88822. doi: 10.1371/journal.pone.0088822. eCollection 2014.
• [455] Changes in immunohistochemical levels and subcellular localization after therapy and correlation and colocalization with CD68 suggest a pathogenetic role of Hsp60 in ulcerative colitis.Appl Immunohistochem Mol Morphol. 2011 Dec;19(6):552-61. doi: 10.1097/PAI.0b013e3182118e5f.
• [456] Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study.Inflamm Bowel Dis. 2008 Apr;14(4):542-9. doi: 10.1002/ibd.20310.
• [457] Identification of the polymorphisms in IFITM1 gene and their association in a Korean population with ulcerative colitis.Immunol Lett. 2013 Nov-Dec;156(1-2):118-22. doi: 10.1016/j.imlet.2013.09.026. Epub 2013 Oct 10.
• [458] Mechanism and biological significance of the overexpression of IFITM3 in gastric cancer.Oncol Rep. 2014 Dec;32(6):2648-56. doi: 10.3892/or.2014.3522. Epub 2014 Oct 1.
• [459] Phenotypic and Genotypic Characterisation of Inflammatory Bowel Disease Presenting Before the Age of 2 years.J Crohns Colitis. 2017 Jan;11(1):60-69. doi: 10.1093/ecco-jcc/jjw118. Epub 2016 Jun 14.
• [460] Expression and location of IL-17A, E, F and their receptors in colorectal adenocarcinoma: Comparison with benign intestinal disease.Pathol Res Pract. 2018 Apr;214(4):482-491. doi: 10.1016/j.prp.2018.03.011. Epub 2018 Mar 7.
• [461] miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis-Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD.Clin Cancer Res. 2017 Sep 1;23(17):5281-5291. doi: 10.1158/1078-0432.CCR-17-0171. Epub 2017 Jun 9.
• [462] Interleukin-34 sustains inflammatory pathways in the gut.Clin Sci (Lond). 2015 Aug;129(3):271-80. doi: 10.1042/CS20150132.
• [463] Variation in Interleukin 6 Receptor Gene Associates With Risk of Crohn's Disease and Ulcerative Colitis.Gastroenterology. 2018 Aug;155(2):303-306.e2. doi: 10.1053/j.gastro.2018.05.022. Epub 2018 Jul 5.
• [464] Impact of inflammatory bowel disease on Japanese patients' quality of life: results of a patient questionnaire survey.J Gastroenterol. 2017 May;52(5):555-567. doi: 10.1007/s00535-016-1241-x. Epub 2016 Jul 28.
• [465] Population Density and Risk of Inflammatory Bowel Disease: A Prospective Population-Based Study in 13 Countries or Regions in Asia-Pacific.Am J Gastroenterol. 2019 Jan;114(1):107-115. doi: 10.1038/s41395-018-0233-2.
• [466] Differential expression of interleukin-1/Toll-like receptor signaling regulators in microscopic and ulcerative colitis.World J Gastroenterol. 2014 Sep 14;20(34):12249-59. doi: 10.3748/wjg.v20.i34.12249.
• [467] Reducing IRF5 expression attenuates colitis in mice, but impairs the clearance of intestinal pathogens.Mucosal Immunol. 2019 Jul;12(4):874-887. doi: 10.1038/s41385-019-0165-1. Epub 2019 May 3.
• [468] Review article: thiopurines in inflammatory bowel disease.Aliment Pharmacol Ther. 2006 Sep 1;24(5):715-29. doi: 10.1111/j.1365-2036.2006.02980.x.
• [469] Association of KIF21B genetic polymorphisms with ankylosing spondylitis in a Chinese Han population of Shandong Province.Clin Rheumatol. 2015 Oct;34(10):1729-36. doi: 10.1007/s10067-014-2761-5. Epub 2014 Aug 23.
• [470] KFL2 participates in the development of ulcerative colitis through inhibiting inflammation via regulating cytokines.Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4941-4948. doi: 10.26355/eurrev_201808_15633.
• [471] Critical role of Keratin 1 in maintaining epithelial barrier and correlation of its down-regulation with the progression of inflammatory bowel disease.Gene. 2017 Apr 15;608:13-19. doi: 10.1016/j.gene.2017.01.015. Epub 2017 Jan 20.
• [472] Functional Analyses of the Crohn's Disease Risk Gene LACC1.PLoS One. 2016 Dec 13;11(12):e0168276. doi: 10.1371/journal.pone.0168276. eCollection 2016.
• [473] Genetic determinants associated with early age of diagnosis of IBD.Dis Colon Rectum. 2015 Mar;58(3):321-7. doi: 10.1097/DCR.0000000000000274.
• [474] Does Age Affect Surgical Outcomes After Ileal Pouch-Anal Anastomosis in Children?.J Surg Res. 2019 May;237:61-66. doi: 10.1016/j.jss.2019.01.004. Epub 2019 Jan 30.
• [475] Immunohistochemical Profile of Tumor Suppressor Proteins RASSF1A and LATS1/2 in Relation to p73 and YAP Expression, of Human Inflammatory Bowel Disease and Normal Intestine.Pathol Oncol Res. 2020 Jan;26(1):567-574. doi: 10.1007/s12253-018-00575-z. Epub 2019 Jan 2.
• [476] Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.J Crohns Colitis. 2017 Jan;11(1):84-91. doi: 10.1093/ecco-jcc/jjw132. Epub 2016 Jul 27.
• [477] Prostaglandin E-major Urinary Metabolite as a Biomarker for Pediatric Ulcerative Colitis Activity.J Pediatr Gastroenterol Nutr. 2017 Jun;64(6):955-961. doi: 10.1097/MPG.0000000000001477.
• [478] Inhibition of myeloid differentiation 1 specifically in colon with antisense oligonucleotide exacerbates dextran sodium sulfate-induced colitis.J Cell Biochem. 2019 Oct;120(10):16888-16899. doi: 10.1002/jcb.28947. Epub 2019 May 19.
• [479] Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship.Gastroenterology. 2009 Feb;136(2):523-9.e3. doi: 10.1053/j.gastro.2008.10.032. Epub 2008 Oct 25.
• [480] ACF7 regulates inflammatory colitis and intestinal wound response by orchestrating tight junction dynamics.Nat Commun. 2017 May 25;8:15375. doi: 10.1038/ncomms15375.
• [481] Spindle proteins Aurora A and BUB1B, but not Mad2, are aberrantly expressed in dysplastic mucosa of patients with longstanding ulcerative colitis.J Clin Pathol. 2007 Dec;60(12):1403-8. doi: 10.1136/jcp.2006.044305. Epub 2007 Feb 23.
• [482] Genetic polymorphisms of MAFK, encoding a small Maf protein, are associated with susceptibility to ulcerative colitis in Japan.World J Gastroenterol. 2017 Aug 7;23(29):5364-5370. doi: 10.3748/wjg.v23.i29.5364.
• [483] STOP-Colitis pilot trial protocol: a prospective, open-label, randomised pilot study to assess two possible routes of faecal microbiota transplant delivery in patients with ulcerative colitis.BMJ Open. 2019 Nov 11;9(11):e030659. doi: 10.1136/bmjopen-2019-030659.
• [484] The Incidence and Definition of Crohn's Disease of the Pouch: A Systematic Review and Meta-analysis.Inflamm Bowel Dis. 2019 Aug 20;25(9):1474-1480. doi: 10.1093/ibd/izz005.
• [485] Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis.Medicine (Baltimore). 2018 May;97(21):e10807. doi: 10.1097/MD.0000000000010807.
• [486] Tricellulin is regulated via interleukin-13-receptor 2, affects macromolecule uptake, and is decreased in ulcerative colitis.Mucosal Immunol. 2018 Mar;11(2):345-356. doi: 10.1038/mi.2017.52. Epub 2017 Jun 14.
• [487] Paediatric inflammatory bowel disease: review with a focus on practice in low- to middle-income countries.Paediatr Int Child Health. 2019 Feb;39(1):48-58. doi: 10.1080/20469047.2019.1575056.
• [488] TNF--induced down-regulation of CDX2 suppresses MEP1A expression in colitis.Biochim Biophys Acta. 2012 Jun;1822(6):843-51. doi: 10.1016/j.bbadis.2012.01.012. Epub 2012 Feb 3.
• [489] Health Care Cost for Children Newly Diagnosed With Inflammatory Bowel Disease.Inflamm Bowel Dis. 2020 Mar 4;26(4):635-640. doi: 10.1093/ibd/izz183.
• [490] MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces ColitisinMice.Gastroenterology. 2017 Nov;153(5):1363-1377.e6. doi: 10.1053/j.gastro.2017.07.048. Epub 2017 Aug 4.
• [491] Dysregulation of T cell receptor N-glycosylation: a molecular mechanism involved in ulcerative colitis.Hum Mol Genet. 2014 May 1;23(9):2416-27. doi: 10.1093/hmg/ddt632. Epub 2013 Dec 13.
• [492] Polymorphisms of the macrophage inflammatory protein 1 alpha and ApoE genes are associated with ulcerative colitis.Int J Colorectal Dis. 2009 Jan;24(1):13-7. doi: 10.1007/s00384-008-0575-0. Epub 2008 Sep 2.
• [493] HLA antigens and ulcerative colitis in Japan.Digestion. 1977;15(4):286-94. doi: 10.1159/000198014.
• [494] Expression of receptor interacting protein 3 and mixed lineage kinase domain-like protein-key proteins in necroptosis is upregulated in ulcerative colitis.Ann Palliat Med. 2019 Sep;8(4):483-489. doi: 10.21037/apm.2019.07.04. Epub 2019 Aug 12.
• [495] Motilin receptor expression in smooth muscle, myenteric plexus, and mucosa of human inflamed and noninflamed intestine.Inflamm Bowel Dis. 2008 May;14(5):612-9. doi: 10.1002/ibd.20364.
• [496] Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis.Scand J Gastroenterol. 2010 Oct;45(10):1186-96. doi: 10.3109/00365521.2010.499961.
• [497] Genetic polymorphisms of RAGE and risk of ulcerative colitis in a Chinese population.Immunol Lett. 2016 Feb;170:88-94. doi: 10.1016/j.imlet.2015.09.003. Epub 2015 Sep 5.
• [498] Oral Targeted Delivery by Nanoparticles Enhances Efficacy of an Hsp90 Inhibitor by Reducing Systemic Exposure in Murine Models of Colitis and Colitis-Associated Cancer.J Crohns Colitis. 2020 Jan 1;14(1):130-141. doi: 10.1093/ecco-jcc/jjz113.
• [499] Role of major histocompatibility complex class I-related molecules A*A5.1 allele in ulcerative colitis in Chinese patients.Immunology. 2009 Sep;128(1 Suppl):e230-6. doi: 10.1111/j.1365-2567.2008.02953.x. Epub 2008 Nov 7.
• [500] The PSMP-CCR2 interactions trigger monocyte/macrophage-dependent colitis.Sci Rep. 2017 Jul 11;7(1):5107. doi: 10.1038/s41598-017-05255-7.
• [501] Acceptability, tolerability, and safety of fecal microbiota transplantation in patients with active ulcerative colitis (AT&S Study).J Gastroenterol Hepatol. 2020 Mar;35(3):418-424. doi: 10.1111/jgh.14829. Epub 2019 Sep 1.
• [502] Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis.Mediators Inflamm. 2015;2015:659018. doi: 10.1155/2015/659018. Epub 2015 Dec 6.
• [503] Alterations in the composition of the supramucosal defense barrier in relation to disease severity of ulcerative colitis.J Histochem Cytochem. 2006 Dec;54(12):1335-48. doi: 10.1369/jhc.5A6904.2006. Epub 2006 Aug 21.
• [504] A meta-analysis of the relationship between MYO9B gene polymorphisms and susceptibility to Crohn's disease and ulcerative colitis.Hum Immunol. 2016 Oct;77(10):990-996. doi: 10.1016/j.humimm.2016.07.008. Epub 2016 Jul 18.
• [505] DNA methylation of colon mucosa in ulcerative colitis patients: correlation with inflammatory status.Inflamm Bowel Dis. 2011 Sep;17(9):1955-65. doi: 10.1002/ibd.21573. Epub 2011 Jan 6.
• [506] Male-specific association between MT-ND4 11719 A/G polymorphism and ulcerative colitis: a mitochondria-wide genetic association study.BMC Gastroenterol. 2016 Oct 3;16(1):118. doi: 10.1186/s12876-016-0509-1.
• [507] The use of selected neutrophil protein plasma concentrations in the diagnosis of Crohn's disease and ulcerative colitis - a preliminary report.Postepy Hig Med Dosw (Online). 2017 Apr 6;71(0):243-253. doi: 10.5604/01.3001.0010.3810.
• [508] Characteristics of Japanese inflammatory bowel disease susceptibility loci.J Gastroenterol. 2014 Aug;49(8):1217-30. doi: 10.1007/s00535-013-0866-2. Epub 2013 Aug 13.
• [509] Gut Microbiota-Mediated NLRP12 Expression Drives the Attenuation of Dextran Sulphate Sodium-Induced Ulcerative Colitis by Qingchang Wenzhong Decoction.Evid Based Complement Alternat Med. 2019 Apr 2;2019:9839474. doi: 10.1155/2019/9839474. eCollection 2019.
• [510] Exome Sequencing and Genotyping Identify a Rare Variant in NLRP7 Gene Associated With Ulcerative Colitis.J Crohns Colitis. 2018 Feb 28;12(3):321-326. doi: 10.1093/ecco-jcc/jjx157.
• [511] NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease.Mucosal Immunol. 2018 Mar;11(2):562-574. doi: 10.1038/mi.2017.74. Epub 2017 Nov 1.
• [512] Systematic analysis of circadian genes using genome-wide cDNA microarrays in the inflammatory bowel disease transcriptome.Chronobiol Int. 2015;32(7):903-16. doi: 10.3109/07420528.2015.1050726.
• [513] Quantification of P21 mRNA in biopsy specimens of colon tissue at different stages of neoplastic transformation.Folia Histochem Cytobiol. 2001;39 Suppl 2:169-70.
• [514] Overexpression of MTH1 and OGG1 proteins in ulcerative colitis-associated carcinogenesis.Oncol Lett. 2018 Aug;16(2):1765-1776. doi: 10.3892/ol.2018.8812. Epub 2018 May 25.
• [515] Correlation of Intestinal Mucosal Healing and Tight Junction Protein Expression in Ulcerative Colitis Patients.Am J Med Sci. 2019 Mar;357(3):195-204. doi: 10.1016/j.amjms.2018.11.011. Epub 2018 Nov 27.
• [516] Chk1 Promotes DNA Damage Response Bypass following Oxidative Stress in a Model of Hydrogen Peroxide-Associated Ulcerative Colitis through JNK Inactivation and Chromatin Binding.Oxid Med Cell Longev. 2017;2017:9303158. doi: 10.1155/2017/9303158. Epub 2017 Jun 7.
• [517] Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis.Gut. 2012 Apr;61(4):528-34. doi: 10.1136/gut.2011.240978. Epub 2011 Jun 27.
• [518] Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behet's disease.Clin Transl Gastroenterol. 2018 Feb 15;9(2):e133. doi: 10.1038/ctg.2018.1.
• [519] Downregulation of the Deiminase PADI2 Is an Early Event in Colorectal Carcinogenesis and Indicates Poor Prognosis.Mol Cancer Res. 2016 Sep;14(9):841-8. doi: 10.1158/1541-7786.MCR-16-0034. Epub 2016 Jun 8.
• [520] Expression and localization of pannexin-1 hemichannels in human colon in health and disease.Neurogastroenterol Motil. 2013 Jun;25(6):e395-405. doi: 10.1111/nmo.12130. Epub 2013 Apr 17.
• [521] Pannexin-2 is expressed in the human colon with extensive localization in the enteric nervous system.Neurogastroenterol Motil. 2015 May;27(5):672-83. doi: 10.1111/nmo.12541. Epub 2015 Mar 14.
• [522] Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis.Gut. 2008 Apr;57(4):463-7. doi: 10.1136/gut.2007.133132. Epub 2007 Nov 7.
• [523] Genetic Association of Peptidoglycan Recognition Protein Variants with Inflammatory Bowel Disease.PLoS One. 2013 Jun 19;8(6):e67393. doi: 10.1371/journal.pone.0067393. Print 2013.
• [524] Cytomegalovirus in colorectal cancer and idiopathic ulcerative colitis.Rev Inst Med Trop Sao Paulo. 2008 Mar-Apr;50(2):83-7. doi: 10.1590/s0036-46652008000200004.
• [525] A Novel Topical PPAR Agonist Induces PPAR Activity in Ulcerative Colitis Mucosa and Prevents and Reverses Inflammation in Induced Colitis Models.Inflamm Bowel Dis. 2018 Mar 19;24(4):792-805. doi: 10.1093/ibd/izx079.
• [526] DNA Methylation Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis.J Crohns Colitis. 2016 Jan;10(1):77-86. doi: 10.1093/ecco-jcc/jjv176. Epub 2015 Sep 28.
• [527] Casticin prevents DSS induced ulcerative colitis in mice through inhibitions of NF-B pathway and ROS signaling.Phytother Res. 2018 Sep;32(9):1770-1783. doi: 10.1002/ptr.6108. Epub 2018 Jun 7.
• [528] Aberrant methylation of the Pleckstrin and Sec7 domain-containing gene is implicated in ulcerative colitis-associated carcinogenesis through its inhibitory effect on apoptosis.Int J Oncol. 2012 Mar;40(3):686-94. doi: 10.3892/ijo.2011.1231. Epub 2011 Oct 13.
• [529] Salivary exosomal PSMA7: a promising biomarker of inflammatory bowel disease.Protein Cell. 2017 Sep;8(9):686-695. doi: 10.1007/s13238-017-0413-7. Epub 2017 May 18.
• [530] Investigation of multiple susceptibility loci for inflammatory bowel disease in an Italian cohort of patients.PLoS One. 2011;6(7):e22688. doi: 10.1371/journal.pone.0022688. Epub 2011 Jul 27.
• [531] Pyoderma gangrenosum, acne and ulcerative colitis in a patient with a novel mutation in the PSTPIP1 gene.Clin Exp Dermatol. 2015 Jun;40(4):367-72. doi: 10.1111/ced.12585. Epub 2015 Feb 16.
• [532] In vitro and in vivo study of pH-sensitive and colon-targeting P(LE-IA-MEG) hydrogel microspheres used for ulcerative colitis therapy.Eur J Pharm Biopharm. 2018 Jan;122:70-77. doi: 10.1016/j.ejpb.2017.10.003. Epub 2017 Oct 7.
• [533] Severity of innate immune-mediated colitis is controlled by the cytokine deficiency-induced colitis susceptibility-1 (Cdcs1) locus.Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7137-41. doi: 10.1073/pnas.1104234108. Epub 2011 Apr 11.
• [534] Post-transcriptional regulator Rbm47 elevates IL-10 production and promotes the immunosuppression of B cells.Cell Mol Immunol. 2019 Jun;16(6):580-589. doi: 10.1038/s41423-018-0041-z. Epub 2018 May 29.
• [535] Isothiocyanate-enriched moringa seed extract alleviates ulcerative colitis symptoms in mice.PLoS One. 2017 Sep 18;12(9):e0184709. doi: 10.1371/journal.pone.0184709. eCollection 2017.
• [536] Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease.Scand J Gastroenterol. 2019 Oct;54(10):1237-1244. doi: 10.1080/00365521.2019.1670251. Epub 2019 Oct 2.
• [537] Upregulation of GRAIL is associated with remission of ulcerative colitis.Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G163-G169. doi: 10.1152/ajpgi.90242.2008. Epub 2008 May 8.
• [538] Regulation of intestinal homeostasis by the ulcerative colitis-associated gene RNF186.Mucosal Immunol. 2017 Mar;10(2):446-459. doi: 10.1038/mi.2016.58. Epub 2016 Jul 6.
• [539] Colonic epithelial mTORC1 promotes ulcerative colitis through COX-2-mediated Th17 responses.Mucosal Immunol. 2018 Nov;11(6):1663-1673. doi: 10.1038/s41385-018-0018-3. Epub 2018 Aug 6.
• [540] Disruption of the p53-p53r2 DNA repair system in ulcerative colitis contributes to colon tumorigenesis.Int J Cancer. 2006 Mar 15;118(6):1395-403. doi: 10.1002/ijc.21538.
• [541] Maresin 1 alleviates dextran sulfate sodium-induced ulcerative colitis by regulating NRF2 and TLR4/NF-kB signaling pathway.Int Immunopharmacol. 2020 Jan;78:106018. doi: 10.1016/j.intimp.2019.106018. Epub 2019 Nov 25.
• [542] Cytokine-dependent transcriptional down-regulation of epithelial sodium channel in ulcerative colitis.Gastroenterology. 2004 Jun;126(7):1711-20. doi: 10.1053/j.gastro.2004.03.010.
• [543] The role of the selenoprotein S (SELS) gene -105G>A promoter polymorphism in inflammatory bowel disease and regulation of SELS gene expression in intestinal inflammation.Tissue Antigens. 2007 Sep;70(3):238-46. doi: 10.1111/j.1399-0039.2007.00888.x.
• [544] Semaphorin-3E attenuates intestinal inflammation through the regulation of the communication between splenic CD11C(+) and CD4(+) CD25(-) T-cells.Br J Pharmacol. 2019 May;176(9):1235-1250. doi: 10.1111/bph.14614. Epub 2019 Apr 1.
• [545] Associations Between the Prognostic Nutritional Index and Morbidity/Mortality During Intestinal Resection in Patients with Ulcerative Colitis.World J Surg. 2018 Jul;42(7):1949-1959. doi: 10.1007/s00268-017-4411-y.
• [546] Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions.Dig Dis Sci. 2007 Sep;52(9):2287-91. doi: 10.1007/s10620-007-9755-y. Epub 2007 Apr 5.
• [547] Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans.FASEB J. 2016 Aug;30(8):2945-58. doi: 10.1096/fj.201600394R. Epub 2016 Apr 29.
• [548] Cyclin D1 and p21 in ulcerative colitis-related inflammation and epithelial neoplasia: a study of aberrant expression and underlying mechanisms.Hum Pathol. 2003 Jun;34(6):580-8. doi: 10.1016/s0046-8177(03)00125-4.
• [549] Neutrophils in ulcerative colitis: a review of selected biomarkers and their potential therapeutic implications.Scand J Gastroenterol. 2017 Feb;52(2):125-135. doi: 10.1080/00365521.2016.1235224. Epub 2016 Sep 27.
• [550] Monocyte-derived macrophages from Crohn's disease patients are impaired in the ability to control intracellular adherent-invasive Escherichia coli and exhibit disordered cytokine secretion profile.J Crohns Colitis. 2015 May;9(5):410-20. doi: 10.1093/ecco-jcc/jjv053. Epub 2015 Mar 24.
• [551] Cross-talk between Colon Cells and Macrophages Increases ST6GALNAC1 and MUC1-sTn Expression in Ulcerative Colitis and Colitis-Associated Colon Cancer.Cancer Immunol Res. 2020 Feb;8(2):167-178. doi: 10.1158/2326-6066.CIR-19-0514. Epub 2019 Dec 12.
• [552] Altered expression of epimorphin in ulcerative colitis.J Gastroenterol Hepatol. 2003 May;18(5):570-7. doi: 10.1046/j.1440-1746.2003.02972.x.
• [553] Integrative analysis of transcriptome-wide association study data and messenger RNA expression profiles identified candidate genes and pathways for inflammatory bowel disease.J Cell Biochem. 2019 Sep;120(9):14831-14837. doi: 10.1002/jcb.28744. Epub 2019 Apr 22.
• [554] Investigation of novel biomarkers for predicting the clinical course in patients with ulcerative colitis.J Gastroenterol Hepatol. 2018 Dec;33(12):1975-1983. doi: 10.1111/jgh.14297. Epub 2018 Jul 18.
• [555] DNA hypermethylation of a selective gene panel as a risk marker for colon cancer in patients with ulcerative colitis.Int J Mol Med. 2013 May;31(5):1255-61. doi: 10.3892/ijmm.2013.1317. Epub 2013 Mar 26.
• [556] Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4.Hepatology. 2013 Sep;58(3):1074-83. doi: 10.1002/hep.25977. Epub 2013 Jan 17.
• [557] Association of ulcerative colitis with transcobalamin II gene polymorphisms and serum homocysteine, vitamin B(12), and folate levels in Chinese patients.Immunogenetics. 2017 Jul;69(7):421-428. doi: 10.1007/s00251-017-0998-2. Epub 2017 May 19.
• [558] A variant form of the human deleted in malignant brain tumor 1 (DMBT1) gene shows increased expression in inflammatory bowel diseases and interacts with dimeric trefoil factor 3 (TFF3).PLoS One. 2013 May 15;8(5):e64441. doi: 10.1371/journal.pone.0064441. Print 2013.
• [559] Transcriptome meta-analysis identifies immune signature comprising of RNA binding proteins in ulcerative colitis patients.Cell Immunol. 2018 Dec;334:42-48. doi: 10.1016/j.cellimm.2018.09.003. Epub 2018 Sep 21.
• [560] TIGAR is required for efficient intestinal regeneration and tumorigenesis.Dev Cell. 2013 Jun 10;25(5):463-77. doi: 10.1016/j.devcel.2013.05.001. Epub 2013 May 30.
• [561] Genetic variation and expression levels of tight junction genes identifies association between MAGI3 and inflammatory bowel disease.BMC Gastroenterol. 2017 May 25;17(1):68. doi: 10.1186/s12876-017-0620-y.
• [562] Hyaluronan Accelerates Intestinal Mucosal Healing through Interaction with TSG-6.Cells. 2019 Sep 12;8(9):1074. doi: 10.3390/cells8091074.
• [563] Epidemiology of inflammatory bowel disease in the Republic of San Marino: The "EPIMICI - San Marino" study.Dig Liver Dis. 2019 Feb;51(2):218-225. doi: 10.1016/j.dld.2018.08.016. Epub 2018 Aug 20.
• [564] Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions.Inflamm Bowel Dis. 2013 Mar;19(3):461-70. doi: 10.1097/MIB.0b013e3182802bac.
• [565] Up-regulation and pre-activation of TRAF3 and TRAF5 in inflammatory bowel disease.Int J Med Sci. 2013;10(2):156-63. doi: 10.7150/ijms.5457. Epub 2013 Jan 3.
• [566] No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.Am J Gastroenterol. 2018 Aug;113(8):1197-1205. doi: 10.1038/s41395-018-0144-2. Epub 2018 Jun 21.
• [567] TRIM58 Restrains Intestinal Mucosal Inflammation by Negatively Regulating TLR2 in Myeloid Cells.J Immunol. 2019 Sep 15;203(6):1636-1649. doi: 10.4049/jimmunol.1900413. Epub 2019 Aug 5.
• [568] Enterovirulent E. coli in inflammatory and noninflammatory bowel diseases.Folia Microbiol (Praha). 2009;54(1):81-6. doi: 10.1007/s12223-009-0012-y. Epub 2009 Mar 29.
• [569] Association of the RAVER2 gene with increased susceptibility for ulcerative colitis.Hum Immunol. 2012 Jul;73(7):732-5. doi: 10.1016/j.humimm.2012.04.018. Epub 2012 May 2.
• [570] Polymorphisms of the apoptosis-associated gene DP1L1 (deleted in polyposis 1-like 1) in colon cancer and inflammatory bowel disease.J Cancer Res Clin Oncol. 2010 Jun;136(6):795-802. doi: 10.1007/s00432-009-0719-9. Epub 2009 Nov 19.
• [571] Two-stage candidate gene study of chromosome 3p demonstrates an association between nonsynonymous variants in the MST1R gene and Crohn's disease.Inflamm Bowel Dis. 2008 Apr;14(4):500-7. doi: 10.1002/ibd.20365.